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The management of blood glucose levels and the avoidance of diabetic hyperglycemia are common
objectives of many therapies in the treatment of diabetes. An aryl piperazine compound 3a (RTC1) has
been described as a promoter of glucose uptake, in part through a cellular mechanism that involves
inhibition of NADH:ubiquinone oxidoreductase. We report herein the synthesis of 41 derivatives of 3a
(RTC1) and a systematic structure-activity-relationship study where a number of compounds were
shown to effectively stimulate glucose uptake in vitro and inhibit NADH:ubiquinone oxidoreductase. The
hit compound 3a (RTC1) remained the most efﬁcacious with a 2.57 fold increase in glucose uptake
compared to vehicle control and micromolar inhibition of NADH:ubiquinone oxidoreductase
(IC50 ¼ 27 mM). In vitro DMPK and in vivo PK studies are also described, where results suggest that 3a
(RTC1) would not be expected to provoke adverse drug-drug interactions, yet be readily metabolised,
avoid rapid excretion, with a short half-life, and have good tissue distribution. The overall results indicate
that aryl piperazines, and 3a (RTC1) in particular, have potential as effective agents for the treatment of
diabetes.
© 2020 Elsevier Masson SAS. All rights reserved.
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1. Introduction
Type 2 diabetes mellitus (T2DM) has become one of the great
modern public health threats in terms of human, social, and economic costs [1]. T2DM is a chronic condition where blood glucose
levels are raised due to the body’s inability to produce enough of
the hormone insulin or to use insulin effectively. Insulin is an
essential hormone produced in the pancreas and plays a critical
role in the transport of glucose from the bloodstream into the
body’s cells. A lack of insulin or a cells insensitivity to insulin leads
to elevated blood glucose levels and hyperglycaemia, which if left
unchecked can result in organ damage and the development of
disabling and life-threatening health complications [1,2].
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The numbers suffering from diabetes are immense and are
increasing at an alarming rate. In 2017, there were ~425 million
diabetic sufferers over the age of 20, and this number is conservatively projected to increase to ~629 million in 2045 [1,2]. There
are a number of therapeutic options available, some of which can be
administered in the early stages of the development of T2DM or as a
combination therapy with injectables. There are several classes of
hypoglycemic agents found in the clinic, including metformin,
sulfonylureas, thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists and insulin, but the control of
diabetes remains variable and unsatisfactory [2e4]. The therapeutic regimens, side effects, and possible off-target actions of
some of these options are undesirable and can lead to reduced
compliance [5e8]. As a consequence, taking into account the projected and rapid growth in the number of those suffering with
diabetes, there is an ever-increasing demand for novel anti-diabetic
therapies with deﬁned mechanisms of action.
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A common objective for many therapies is the management of
blood glucose levels and the avoidance of diabetic hyperglycemia.
Different strategies can be employed to achieve this including the
stimulation of glucose uptake from the bloodstream, reducing
gluconeogenesis, and increasing glucose excretion [3,4]. Therapeutics that increase insulin secretion or increase insulin sensitivity
will typically result in an increase in glucose uptake and a reduction
in diabetic hyperglycemia. Diabetic hyperglycemia has also been
reported to aberrantly upregulate complex I activity in the
pancreas, which suggest that complex I could be a promising
therapeutic target for diabetes [8,9]. We recently reported the
piperazine containing compounds RTC1 and RTB70, which act
through the inhibition of NADH:ubiquinone oxidoreductase
(complex I of the mitochondrial respiratory chain) to stimulate
glucose uptake and restore the glucose handling abilities of diabetic
mice [10,11]. The reduction in NADH:ubiquinone oxidoreductase
activity provoked by these compounds leads to a change in cellular
ADP:ATP and AMP:ATP ratios resulting in the activation of AMPactivated protein kinase (AMPK). Once activated, AMPK rapidly
restores cellular energy balance by switching off ATP consuming
anabolic pathways and by switching on ATP generating catabolic
pathways involving increased glucose uptake [12]. Further studies
showed that RTC1 augmented the signalling capabilities of insulin
in C2C12 cells stimulated with tumour necrosis factor-alpha (TNFa), thus preventing TNF-a induced insulin resistance through action
as an insulin sensitizer [13]. As a result, a systematic analysis of
these compounds was conducted to further explore their ability to
stimulate glucose uptake and use as a potential therapeutic strategy
for T2DM.
Herein, we report the synthesis and evaluation of derivatives of
compound 3a (RTC1). The study involved the systematic modiﬁcation of 3a (RTC1) at ﬁve sites, A-E (Fig. 1), in order to explore the
relationship between chemical structure and biological activity.
This approach allowed us to investigate the importance of the aryl
substituent (site A), the nature of the aryl group (site B), the
piperazine (site C), the length and nature of the alkyl chain (site D),
as well as the terminal group (site E) on the ability to stimulate
glucose uptake. Compounds were evaluated for their in vitro ability
to stimulate glucose uptake and, in a number of cases, for the
inhibitory activity against NADH:ubiquinone oxidoreductase in
permeabilised mitochondria. A pharmacophore was developed
based on the effectiveness of the compound library at stimulating
glucose uptake, with preliminary drug metabolism and pharmacokinetic (DMPK) studies also conducted with the hit compound 3a
(RTC1).

2. Results and discussion
2.1. Synthesis of hit compound 3a (RTC1)
A total of 41 derivatives of the hit compound 3a (RTC1) were
synthesised as shown in Scheme 1. The hit compound 3a (RTC1)
was generated in a two-step process. The intermediate aryl piperazine
2a was
synthesised
in
50%
yield
from 4chlorobenzotriﬂuoride 1a and piperazine by heating to 200  C

Fig. 1. Chemical structure of 3a (RTC1) and sites A-E for pharmacomodulation.

under microwave conditions. Subsequent coupling of 2a with the
commercially available 4-(2-thienyl)butyric acid generated the
desired product, 3a (RTC1), in 86% yield (Scheme 1) [10].
2.2. Synthesis of derivatives with variations at site A-E
The ﬁrst structural modiﬁcations made were those concerned
with variations at site A, the substitution pattern of the aryl ring,
and were undertaken in order to study the effect and importance of
the CF3 substituent on activity. This involved (i) variation of the para
substituent on the aryl ring (3a-3f); (ii) changing the position of the
CF3 substituent (3g), and (iii) bis substitution of the aryl ring (3h-j)
(Table 1). The key intermediate, the aryl piperazine, was commercially available in some but not all cases. The bis-substituted 1-(2chloro-4-(triﬂuoromethyl)phenyl)piperazine 2i and 1-(2-bromo4-(triﬂuoromethyl)phenyl)piperazine 2j were both synthesised
from the corresponding aryl chloride and piperazine via an SNAr
reaction in NMP under microwave conditions (Scheme 1, (a)). The
alkyl substituted 1-(p-tolyl)piperazine 2c could not be generated by
this method, and instead was synthesised from the corresponding
aniline and bis(2-chloroethyl)amine via a substitution/cyclisation
sequence (Scheme 1, (b)). The ﬁnal step in the synthesis of compounds 3a-j was the coupling reaction between the aryl piperazine
and 4-(2-thienyl)butyric acid, using HOBt and TBTU as coupling
reagents (Scheme 1, (c)). This method gave the desired products in
yields ranging from 24 to 86% for the ﬁnal step. Compound 3f was
generated from the para-nitro substituted 3e via the reduction of
the nitro group using H2 over PtO2 in a 57% yield.
We next explored variations of the aryl ring, site B. To do this,
the aryl ring was changed to a substituted pyridine (5a-c) as well as
cyclic and acyclic alkyl groups (5d-e) (Scheme 1, Table 1). In all
cases, 5a-e, the corresponding piperazines were commercially
available, which allowed the target compounds to be synthesised in
a single coupling reaction with yields ranging from 68 to 91%.
Changes at site C allowed us to explore the importance of the
piperazine ring. This required the synthesis of compounds 7a-c,
where the piperazine ring was replaced with a piperidine ring (7a),
a hydrazine group (7b), and an NH (7c) (Scheme 1, Table 2). The
appropriate starting amine or hydrazine for each target compound
were commercially available, with subsequent coupling using 4-(2thienyl)butyric acid generating 7a-c in a single step (Scheme 1,
67e90% yield).
Exploration of site D required the synthesis of derivatives with
variations in the alkyl chain linking the piperazine motif and the
thiophene heterocycle. This included the generation of compounds
9a-e, where the changes in the alkyl chain length was investigated
through sequential addition of single methylene units (Scheme 1,
Table 3, 44e82% yield). Compounds 9f-g were also synthesised,
using the same coupling methodology, where additional functional
groups were added to the chain including a sulfur atom and a
carbonyl group (Scheme 1, Table 3, 63e84% yield). The hit compound 3a (RTC1) contains an amide carbonyl group adjacent to the
piperazine ring. The importance of this amide carbonyl for biological activity was explored though the synthesis and evaluation of
compound 12, which lacks the amide carbonyl (Scheme 1, Table 3).
Compound 12 was synthesised via a three step process culminating
in a SN2 type reaction between 1-(4-(triﬂuoromethyl)phenyl)
piperazine and the mesylate ester 11, 70% yield. Mesylate ester 11
was generated by the reduction of the starting carboxylic acid,
followed by mesylation of the resulting primary alcohol 10 (see
experimental section).
The importance of a terminal thiophene heterocycle for biological activity, as found in compound 3a (RTC1), also required
investigation. To explore this we removed the thiophene, replacing
it with a methyl group 14a and a pyrazole heterocycle 14b (Scheme
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Scheme 1. Synthesis of 3a (RTC1) derivatives. Reagents and conditions: A. (a) HOBt, TBTU, NEt3, DMF, overnight, rt; (b) Na2CO3, MeCN, N2 atmosphere, 24 h, reﬂux; (c) EtOH, formic
acid, formaldehyde, 3 h, reﬂux; (d) from compound 16e, 2-methoxyethanamine, HOBt, TBTU, NEt3, DMF, 20 h, rt; (e) from compound 3e, PtO2, H2 atmosphere, 16.5 h, rt. B. (f)
Piperazine, NMP, 30 min, 200  C, MW (2a, R ¼ 4-(triﬂuoromethyl)phenyl, 50% yield; 2i, R ¼ 2-chloro-4-(triﬂuoromethyl)phenyl), 63% yield; 2j, R ¼ 2-bromo-4-(triﬂuoromethyl)
phenyl), 23% yield); (g) (i) bis(2-chloroethyl)amine.HCl, bis(2-methoxyethyl) ether, 16 h, reﬂux, (ii) 5% NaOH (aq.), 4 h, rt (2c, R ¼ p-tolyl, 13% yield). *Other amine/piperazine
intermediates were commercially available. C. (h) HOBt, TBTU, NEt3, DMF, overnight, rt. D. (i) 4-(2-Thienyl)butyric acid, HOBt, TBTU, NEt3, DMF, overnight, rt.

1, Table 4). Both 14a and 14b were synthesised in a single step from
the corresponding carboxylic acid and 1-(4-(triﬂuoromethyl)
phenyl)piperazine in a 57% and 10% yield respectively.
Finally, we undertook an investigation where variations were
made at more than one site. This allowed us to explore additional
chemical space and the effect that multiple structural variations
would have on biological activity. Analogues 16a-f were synthesised with variations at both sites D and E (Scheme 1, Table 5).
Here variations included methyl, furyl, and ester terminal groups as
replacements for the thiophene heterocycle in 3a (RTC1), as well as
variations in chain length. All compounds, except 16g, were synthesised in a single coupling step (Scheme 1, 31e98% yield). Compound 16g required an additional step where compound 16e was
coupled with 2-methoxyethanamine to give compound 16g
(Table 5). Compound 17 was also generated, where the entire alkyl
chain-thiophene ring motif is removed, using formic acid and
formaldehyde (Scheme 1, Table 5, 70% yield). Compound 18, with
variations at site C and D, was synthesised in a single step from the
commercially available 4-(4-triﬂuoromethyl)phenyl)piperidine and
4-oxo-4-(2-thienyl)butanoic acid (Scheme 1, Table 5, 87% yield).

Compounds 19e21 had variations at both B and D sites and were
generated using the same one step process from commercially
available starting (Scheme 1, Table 5, 63e71% yield). Compound 22
was synthesised, with variations at both the A and C sites, where
the CF3 substituent of 3a (RTC1) is removed from the aryl ring and
the piperazine saturated heterocycle is replaced by a piperidine
(Scheme 1, Table 5, 98% yield). Finally, compound 23 was purchased
from a commercial supplier, with compound 24 generated by the
straight forward esteriﬁcation of 23.
2.3. In vitro evaluation of glucose uptake by 3a (RTC1) and its
derivatives
With the desired compounds in hand, we next undertook the
evaluation of their ability to stimulate glucose uptake in C2C12
mouse muscle cells using a tritiated version of deoxy-2-glucose, a
derivative of glucose that cannot be metabolised [10,14]. Results
from this assay are presented as fold change, induced with a 10 mM
treatment, compared with the vehicle control, DMSO (Tables 1e5).
The in vitro glucose uptake data revealed that chemical structure
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Table 1
In vitro glucose uptake activity of compounds with variations at sites A, 3a-j, and site B, 5a-e.

Compound

R

Glucose uptake
Fold change ± SEM

Active (Y) with p-value or inactive (N)

3a (RTC1)

2.57 ± 0.08

Y (***)

3b

0.96 ± 0.07

N

3c

1.00 ± 0.42

N

3d

1.16 ± 0.09

N

3e

1.06 ± 0.10

N

3f

1.32 ± 0.12

N

3g

0.85 ± 0.02

N

3h

1.42 ± 0.09

Y (*)

3i

1.58 ± 0.15

Y (***)

3j

1.02 ± 0.04

N

5a

1.00 ± 0.09

N

5b

1.22 ± 0.10

N

5c

1.13 ± 0.02

Y (*)

5d

1.29 ± 0.04

Y (***)

5e

0.84 ± 0.03

N

All data are expressed as means ± standard error of the means (SEM) of a number of experiments (n) performed for that compound. Statistical analysis was performed using
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95% conﬁdence in result) or a one star signiﬁcance
(*), p-value < 0.01 or two stars signiﬁcance (**), and p-value < 0.0001 or three stars signiﬁcance (***). Only compounds which received stars signiﬁcance in the glucose uptake
assay were considered “active” compounds. Full experimental details can be found in the experimental section and supporting information.

had a signiﬁcant impact on activity. Full experimental details can be
found in the experimental section and supporting information.

2.3.1. In vitro glucose uptake for site a modiﬁcations
For site A modiﬁcations, which entail changes to the substitution of the aryl ring, all results showed a reduction or loss of glucose
uptake activity compared to 3a (RTC1) (Fig. 1, Table 1). Removal of
the p-CF3 substituent (3b), or its replacement with the smaller
hydrophobic methyl (3c) substituent, resulted in a complete loss of

activity. Replacing the CF3 substituent with a single ﬂuorine atom
(3d), or another electron withdrawing substituent such as a nitro
substituent (3e), resulted in complete loss of activity, as did its
replacement with the electron donating amino substituent (3f).
Moving the CF3 substituent from the para to the ortho position (3g)
also resulted in complete loss of activity. The only A type modiﬁcations that resulted in active compounds, albeit with reduced
activity, was the replacement of the p- CF3 substituent with two
meta CF3 substituents (3h) or keeping the p-CF3 substituent and

R. Devine et al. / European Journal of Medicinal Chemistry 202 (2020) 112416
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Table 2
In vitro glucose uptake activity of compounds 7a-c.

Compound

Y

7a

7b
7c

NH

Glucose uptake
Fold change ± SEM

Active (Y) with p-value or inactive (N)

2.14 ± 0.30

Y (***)

1.24 ± 0.05

Y (**)

1.11 ± 0.08

N

All data are expressed as means ± standard error of the means (SEM) of a number of experiments (n) performed for that compound. Statistical analysis was performed using
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95% conﬁdence in result) or a one star signiﬁcance (*), p-value < 0.01 or two stars signiﬁcance (**), and p-value < 0.0001 or three stars signiﬁcance (***). Only compounds which received stars signiﬁcance in the
glucose uptake assay were considered “active” compounds. Full experimental details can be found in the experimental section and supporting information.

Table 3
In vitro glucose uptake activity of compounds 3a, 9a-g, and 12.

Compound

Z

Glucose uptake
Fold change ± SEM

Active (Y) with p-value or inactive (N)

9a

0.93 ± 0.07

N

9b

1.33 ± 0.04

Y (***)

9c

1.09 ± 0.08

N

3a (RTC1)

2.57 ± 0.08

Y (***)

9d

1.78 ± 0.13

Y (***)

9e

1.33 ± 0.05

Y (***)

9f

2.14 ± 0.23

Y (***)

9g

1.19 ± 0.03

Y (***)

12

1.36 ± 0.09

Y (***)

All data are expressed as means ± standard error of the means (SEM) of a number of experiments (n) performed for that compound. Statistical analysis was performed using
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95% conﬁdence in result) or a one star signiﬁcance
(*), p-value < 0.01 or two stars signiﬁcance (**), and p-value < 0.0001 or three stars signiﬁcance (***). Only compounds which received stars signiﬁcance in the glucose uptake
assay were considered “active” compounds. Full experimental details can be found in the experimental section and supporting information.
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Table 4
In vitro glucose uptake activity of compounds 14a-b and 16a-g.

Compound

R

Glucose uptake
Fold change ± SEM

Active (Y) with p-value or inactive (N)

14a

1.28 ± 0.11

Y (**)

14b

1.35 ± 0.11

Y (**)

16a

1.43 ± 0.09

Y (***)

16b

1.38 ± 0.05

Y (***)

16c

1.95 ± 0.09

Y (***)

16d

1.11 ± 0.04

N

16e

1.38 ± 0.06

Y (***)

16f

1.08 ± 0.08

N

16g

2.35 ± 0.25

Y (***)

All data are expressed as means ± standard error of the means (SEM) of a number of experiments (n) performed for that compound. Statistical analysis was performed using
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95% conﬁdence in result) or a one star signiﬁcance
(*), p-value < 0.01 or two stars signiﬁcance (**), and p-value < 0.0001 or three stars signiﬁcance (***). Only compounds which received stars signiﬁcance in the glucose uptake
assay were considered “active” compounds. Full experimental details can be found in the experimental section and supporting information.

adding an ortho-Cl substituent (3i). From the type A results, it can
be suggested that the presence of a CF3 substituent on the aromatic
ring is important for biological activity, and that a single CF3 substituent at the para position is preferable over two CF3 substituents.
CF3 substituents are well known for the hydrophobic and lipophilic
nature, and can aid transport across cell membranes, as well as
contribute to binding in hydrophobic enzyme pockets [15,16].
2.3.2. In vitro glucose uptake for site B modiﬁcations
For site B modiﬁcations changes were made to the aryl ring itself
(Fig. 1, Table 1). The employment of a pyridine ring in place of the
phenyl ring resulted in compound 5a, which was inactive in the
glucose uptake assay. Compound 5c, containing a 3-chloro-5-(triﬂuoromethyl)pyridine in place of the phenyl ring, gave statistically
signiﬁcant activity but at a low level and considerably lower than
3a (RTC1). Replacing the aromatic ring with an aliphatic cyclohexyl
ring (5d) did generate an active compound but again with activity
levels lower than 3a (RTC1). Replacement of the aryl ring with a
simple aliphatic acyclic group (methyl, 5e) resulted in complete loss
of activity. The results for compounds 5a-5e suggest that the
presence of an aryl ring is important for activity and replacement
with a pyridine or aliphatic ring has a detrimental effect on activity
levels.
2.3.3. In vitro glucose uptake for site C modiﬁcations
Three compounds were evaluated with site C modiﬁcations
(Fig. 1, Table 2). Here, replacement of the piperazine ring with a
piperidine ring (7a) resulted in an active compound with a 2-fold
increase in activity compared to the vehicle control. Although a
strong result, the piperidine containing 7a was still less active that
3a (RTC1), which itself generated a 2.5-fold increase in activity.
Surprisingly, replacement of the piperazine ring with a hydrazine
motif (7b) resulted in an active compound, albeit with a considerably lower level of activity than 3a (RTC1). The third site C

compound evaluated was 7c, where the piperazine ring was
replaced by an NH group, creating an amide linkage between the
aryl ring and the rest of the molecule. As one might have expected,
this generated a compound that was inactive in the glucose uptake
assay. The set of results generated under site C modiﬁcations would
suggest that the presence of a piperazine ring is optimal for activity,
but that replacement with a piperidine ring does not dramatically
reduce activity.
2.3.4. In vitro glucose uptake for site D modiﬁcations
Site D modiﬁcations involved the study of the length and nature of the chain connecting the piperazine ring to the thiophene
heterocycle. Here, most of the compounds generated could
effectively stimulate glucose uptake to some degree, although all
were less active than 3a (RTC1) (Fig. 1, Table 3). Compounds 9a-9e
explored the length of the methylene chain, with 9a having no
methylene chain and 9e having a ﬁve carbon chain in place. The
results for 9a-9e suggest that the alkyl chain in 3a (RTC1) is
important for biological function, as activity was lost when the
chain was completely removed in compound 9a. Activity was also
reduced when the alkyl chain was shortened but not fully
removed, as was the case for compound 9c (not active). Lengthening the alkyl chain (9d and 9e) also resulted in a decrease in
activity, but not a complete loss in activity. One possible explanation is that a certain alkyl chain length is required for the
molecule to bind strongly in an active/binding site. Too short or
too long a chain may result in a poor ﬁt and weak binding. Also, an
entropy effect could also be considered for the longer chain
compounds. The longer chain compounds are able to adopt a
larger number of conformations when unbound. As such, upon
binding there will be a larger increase in order, entropy cost, and
hence the binding of such molecules may be less thermodynamically favourable when compare to the shorter chained 3a (RTC1)
[17,18].
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Table 5
In vitro glucose uptake activity of compounds 18e22, 23, 2a, 24, and 17.
Compound

Structure

Glucose uptake
Fold change ± SEM

Active (Y) with p-value or inactive (N)

18

1.31 ± 0.05

Y (***)

19

1.22 ± 0.06

N

20

1.26 ± 0.06

Y (*)

21

1.31 ± 0.02

Y (***)

22

1.25 ± 0.12

Y (*)

23

1.16 ± 0.04

Y (*)

2a

1.16 ± 0.06

Y (*)

24

1.09 ± 0.04

N

17

0.92 ± 0.07

N

All data are expressed as means ± standard error of the means (SEM) of a number of experiments (n) performed for that compound. Statistical analysis was performed using
one-way analysis of variance (ANOVA) using GraphPad Prism 5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95% conﬁdence in result) or a one star signiﬁcance
(*), p-value < 0.01 or two stars signiﬁcance (**), and p-value < 0.0001 or three stars signiﬁcance (***). Only compounds which received stars signiﬁcance in the glucose uptake
assay were considered “active” compounds. Full experimental details can be found in the experimental section and supporting information.

The importance of the carbonyl group in 3a (RTC1) was explored
by generating a derivative (12) where this functional group was
absent. Compound 12 was considerably less active that 3a (RTC1),
although activity was not completely eliminated suggesting that
the presence of the carbonyl group was important for activity but
not absolutely essential (Table 3). Compounds 9f and 9g all contained modiﬁcations to the methylene chain but kept the carbonyl
group. These included replacing a methylene unit with a sulfur
atom (9f) or a carbonyl group (9g). All were less active than 3a
(RTC1), although compound 9f containing the S atom, showed a 2fold increase in activity compared to vehicle control. This result
compared favourably with the 2.57-fold increase observed for 3a
(RTC1).

2.3.5. In vitro glucose uptake for (i) site E modiﬁcations and (ii) a
combination of both site D & site E modiﬁcations
Two compounds were evaluated with site E modiﬁcations (14a
and 14b) (Fig. 1, Table 4). Both compounds were active with statistical signiﬁcance but were considerably less active than 3a
(RTC1), suggesting that a thiophene ring at site E is not essential for
activity but that its replacement results in reduced activity.
The effect of modifying both sites D & E simultaneously was
explored with compounds 16a-g (Fig. 1, Table 4). Here, all compounds except 16d and 16f were active with statistical signiﬁcance.

However, all compounds were less active that 3a (RTC1), with 16c
and 16g proving most active with a 1.95- and 2.35-fold increase,
respectively, compared to the vehicle control. This compares
favourably to the 2.57-fold increase of 3a (RTC1). The results in
Table 4 suggest that structural modiﬁcation at the D-E sites of the
molecule is better tolerated than those at the A-B sites.

2.3.6. In vitro glucose uptake for modiﬁcations at a combination of
sites
A further ﬁve compounds (18e22) with modiﬁcations at more
than one site were also evaluated for their ability to stimulate
glucose uptake in vitro (Table 5). As expected, given the effects of
the single modiﬁcations, these compounds generated lower levels
of glucose uptake compared to 3a (RTC1). Four of the ﬁve compounds gave low, but statistically signiﬁcant levels of activity.
Compound 22 perhaps generated the most surprising result, as
earlier results for compound 3b, where the CF3 substituent was
removed, generated an inactive compound. However, the activity of
compound 22 was quite low with a 1.25 ± 0.12 fold change
compared to vehicle control. Compound 3a (RTC1) containing both
the CF3 and a piperazine ring, and compound 7a containing both
the CF3 and the piperidine ring, generated substantially higher
levels of activity than compound 22 (2.57 fold change and 2.14 fold
change respectively). This would again suggest that the presence of
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the CF3 is important for activity.
The starting materials used in the synthesis of 3a (RTC1), namely
compounds 23 and 2a, along with their methylated forms (24 and
17), were also evaluated (Table 5). Both starting materials showed
very low levels of activity, with their methylated forms proving to
be inactive. This set of results would suggest that neither the thiophone alkyl chain (23, 24), nor the aryl piperazine (2a, 17) alone is
sufﬁcient to stimulate glucose uptake, and that a more complex
molecule is required. It also suggests that 3a (RTC1) is not acting as
a prodrug, with cleavage/hydrolysis in vitro generating the starting
materials as the active compounds.
2.4. Molecular modelling
The key features that are responsible for biological function
were identiﬁed using pharmacophore model generation (Biovia,
Discovery Studio). These features consisted of 4 hydrophobics
(covering sites A, B, C and E) and a hydrogen bond acceptor (HBA)
feature covering site D and 4 exclusion volumes deﬁning the shape
of the pocket (Fig. 2). One mis-matched feature was permitted for
compound alignment to the pharmacophore. For example, the
importance of the carbonyl group in 3a (RTC1) was explored by
analogue 12 which was missing this functional group. While
compound 12 was considerably less active that 3a (RTC1), the activity was not completely eliminated suggesting that the presence
of the carbonyl group was important for activity but not absolutely
essential. Hence, additional ﬂexibility was incorporated into the
pharmacophore model. A distinction is observed between the ﬁt to
the pharmacophore of a very active compound such as 3a (RTC1)
(Fig. 2), with a 2.57-fold change in the glucose uptake assay
(Table 4), and many inactive compounds. Hence, the pharmacophore model could be beneﬁcial in future SAR optimisation of the
compounds for the glucose uptake assay.
2.5. In vitro evaluation of NADH:ubiquinone oxidoreductase
inhibition by 3a (RTC1) and its derivatives
Both 3a (RTC1) and 21 (RTB70) have been reported by this group
to act through the inhibition of NADH:ubiquinone oxidoreductase
(complex I of the mitochondrial respiratory chain), stimulating

glucose uptake and restoring the glucose handling abilities of diabetic mice [10]. As such, a number of the most active compounds in
this glucose uptake study were evaluated for their inhibitory activity against NADH:ubiquinone oxidoreductase in permeabilised
mitochondria (Table 6). For comparison, a number of the inactive
compounds were also evaluated in the NADH:ubiquinone oxidoreductase assay (Table 6). All of the active compounds evaluated
were also found to be active in the NADH:ubiquinone oxidoreductase assay. The compounds that were most active in the glucose
uptake assay were not necessarily the most active in the NADH:ubiquinone oxidoreductase assay (Table 6). This may be due to
the difference between a whole cell assay system and an inhibition
assay, where for the latter the cell membrane and other cellular
machinery have been removed. Furthermore, and to our surprise,
all of the inactive compounds evaluated showed some activity in
the NADH:ubiquinone oxidoreductase assay (Table 6). One possible
explanation is that in the whole cell glucose uptake assay, the
compounds could not pass the cell membrane, avoid efﬂux mechanisms, or survive the cells internal machinery (e.g. hydrolysis,
enzyme catalysed degradation) and hence were inactive [19]. In an
inhibition assay, such as the NADH:ubiquinone oxidoreductase
assay, these barriers and challenges are removed, and this could
allow the compounds to access the complex I active site and inhibit
its activity. As such, whole cell assay systems can be useful indicators of in vivo biological potency. Hollenback et al. have reported a similar trend in their research where they tested substrate
speciﬁcity in membrane and whole cell assays [20]. Research by
Hernandez et al. also compared enzyme assays with a whole cell
based assay. They concluded that whole cell based assays have the
advantage of only selecting compounds that are able to penetrate
cells and reach the intracellular targets [21].
2.6. Predicted physiochemical properties
In general, the compounds are predicted to have low-to-good
solubility, good absorption properties, and high-to-medium predicted blood brain barrier (BBB) penetration (Biovia Discovery
Studio). These ADMET screening results are summarized in
Tables 1e7 of the supplementary information. For example, compound 3a (RTC1) is predicted to have a low solubility; good absorption and to readily pass the BBB. It is also likely to bind well to
plasma proteins and not to be hepatotoxic.
2.7. Physiochemical properties, in vitro DMPK, and in vivo PK of 3a
(RTC1)
A preliminary study was undertaken in order to offer some
insight into the physiochemical properties, in vitro DMPK, and

Table 6
NADH:ubiquinone oxidoreductase assay results for some of the aryl piperazine
compounds.

Fig. 2. Pharmacophore model with four hydrophobic features (in cyan), a hydrogen
bond acceptor feature (in green), and 4 exclusion volumes (in grey) based on the
inactive compounds. Compound 3a (RTC1), with a 2.57 fold change and a p value of
<0.0001 in the glucose uptake assay, is shown matching the pharmacophore with a ﬁt
value of 1.89. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the Web version of this article.)

Compound

IC50 (mM)

Glucose uptake fold change ± SEM

3a (RTC1)
3i
7a
9d
9f
16c
3ba
3ea
5ea
7ca
17a

27
46
15
60
14
6
133
17
161
92
67

2.57
1.58
2.14
1.78
2.14
1.95
0.96
1.06
0.84
1.11
0.92

a

Inactive in glucose uptake assay.

±
±
±
±
±
±
±
±
±
±
±

0.08
0.15
0.30
0.13
0.23
0.09
0.07
0.10
0.03
0.08
0.07
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Table 7
In vitro assessment of 3a (RTC1) metabolic stability.
Compound

Verapamil
3a (RTC1)
a
b
c
d

Species

Human
Mouse
Human
Mouse

Microsome

Cryopreserved Hepatocytes

T1/2a (min)

CLint

23
24
12
6

60
57
116
226

b

(mL/min/mg)

T1/2a (min)

CLint c (mL/min/106 cells)

E Hd

633
288
3
125

2
3
346
8

0.16
0.29
0.98
0.48

Half-life.
Intrinsic clearance (mL/min/mg).
Intrinsic clearance (mL/min/106 cells).
Hepatic extraction ratio. n ¼ 2, see supporting information.

in vivo PK of 3a (RTC1). The results from this preliminary study are
encouraging, however only tentative conclusions are made due to
the limitations of the study. See supporting information for additional experimental detail and supporting data.
Thermodynamic solubility studies revealed the aqueous solubility of 3a (RTC1) to be 0.004 mg/mL (±0.001 SEM). The low solubility of 3a (RTC1) is believed to be due to the lipophilic properties
of the compound (logP value of 4.79). However, as removal of the
CF3 moiety decreased the logP value and consequentially the activity of derivatives, this property is believed to be central to the
activity of 3a (RTC1), as it may facilitate lipid membrane permeability and promote target engagement. In vitro analysis of Pglycoprotein (P-gp) -mediated efﬂux, in hMDR1-MDCK seeded ﬁlters, demonstrated 3a (RTC1) to be a highly permeable compound
with a passive permeability (Papp) value of 27.1  106 cm/s (±1.9
SD), similar to that of the positive control, propranolol
(21.8  106 cm/s, ± 1.0 SD). Under these conditions 3a (RTC1)
produced an efﬂux ratio of 0.9, suggesting the compound does not
act as a P-gp substrate. The administration of 3a (RTC1) should
therefore not provoke adverse drug-drug interactions [22] as many
observed drug-drug interactions are caused by the inhibition of
both P-gp and the cytochrome P-450 enzymes (CYP450s).
The effect of 3a (RTC1) on recombinant human CYP450 isozymes was also investigated and demonstrated weak-moderate
inhibition of the major human CYP450s and hence a reduced risk
of unwanted drug-drug interactions. CYP1A2 (53.7% inhibition, ±
0.3 SEM), CYP2C9 (74.2% inhibition, ± 3.2 SEM), CYP2C19 (75.5%
inhibition, ± 0.5 SEM), CYP2D6 (2.7% inhibition, ± 4.9 SEMM),
CYP3a4 (80.2% inhibition, ± 1.5 SEM), see supporting information.
Hepatocytes and microsomes were then used to gain an understanding of the way in which 3a (RTC1) would be metabolised.
In both species tested, human and mouse, 3a (RTC1) (1 mM)
demonstrated a shorter half-life and faster intrinsic clearance than
the control drug, verapamil, indicating that 3a (RTC1) would be
readily metabolised by the liver in vivo (Table 7). In addition to this,
3a (RTC1) demonstrated no adverse effects on primary rat hepatocytes, nor did it inhibit the hERG channel [10].
Compound 3a (RTC1) exhibited high mouse and human serum
protein binding (Table 8), which would prevent the rapid excretion
of the compound. Compound 3a (RTC1) was also observed to be
relatively stable in plasma (80% stable at 2 h), indicative of a
compound that would demonstrate good in vivo efﬁcacy.
As with the recent pharmacodynamic study [10], 3a (RTC1)

(10 mg/kg) administered intravenously (IV) or orally to male C57BL/
6 mice produced no observable toxic effects. Following IV administration, 3a (RTC1) had a short half-life of 0.45 h and high plasma
clearance. The compound distributed at high levels into all of the
tissues analysed apart from muscle, following a similar proﬁle to
plasma, with moderate to high clearance. Compound 3a (RTC1) was
also rapidly absorbed following oral dosing, with a similar half-life
to post IV administration at 0.76 h. The tissue levels also show a
similar distribution proﬁle to the plasma proﬁle, as was seen post IV
dosing. Plasma clearance of 3a (RTC1) was in line with that of
mouse liver blood ﬂow (5400 mL/h/kg), indicating metabolism to
be the main route of clearance (Table 9). While 3a (RTC1) exhibited
high mouse and human serum protein binding, it had moderate
bioavailability (21.4%) suggesting the bound portion of 3a (RTC1)
may act as a reservoir or depot from which 3a (RTC1) is slowly
released as the unbound free form.
2.8. Statistical analysis
Data presented herein are expressed as means ± standard error
of the means (SEM) of a number of experiments (n) performed for
that compound. Where possible, statistical analysis was performed
using one-way analysis of variance (ANOVA) using GraphPad Prism
5.0 with a threshold of signiﬁcance deﬁned as a p-value <0.05 (95%
conﬁdence in result) or a one star signiﬁcance (*), p-value < 0.01 or
two stars signiﬁcance (**), and p-value < 0.0001 or three stars
signiﬁcance (***). Only compounds which received stars signiﬁcance in the glucose uptake assay were considered “active”
compounds.
3. Conclusions
To summarise, the synthesis of 41 derivatives of hit compound
3a (RTC1) and a systematic structure-activity-relationship study
are reported where a number of compounds were shown to
effectively stimulate glucose uptake in vitro and inhibit NADH:ubiquinone oxidoreductase. The key structural features responsible
for biological function were also identiﬁed via the generation of a
pharmacophore model. The hit compound 3a (RTC1) remained the
most effective compound of those evaluated, with a 2.57 fold increase in glucose uptake compared to vehicle control and micromolar
inhibition
of
NADH:ubiquinone
oxidoreductase
(IC50 ¼ 27 mM). The presence of a p-CF3 aryl piperazine motif is

Table 8
Serum protein binding and plasma stability of 3a (RTC1).
Compound

Species

Serum Protein Binding (% ± SEM)

Plasma Stability T1/2 (min)

3a (RTC1)

Human
Mouse

99.48 ± 0.04
99.48 ± 0.01

808
327

See supporting information.
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Table 9
Pharmacokinetic properties of 3a (RTC1) in vivo.
Parameter

T1/2 (h)
Tmax (h)
Cmax (ng/mL)
AUClast (h*ng/mL)
AUCall (h*ng/mL)
AUCinf (h*ng/mL)
Cl (mL/h/kg)
Vd (mL/kg)

Plasma

Brain

Kidney

Spleen

Liver

Muscle

Orala

IVb

Orala

IVb

Orala

IVb

Orala

IVb

Orala

IVb

Orala

IVb

0.76
0.25
787
520
520
523

0.45
0.03
996
240
240
244
4102
1686

0.46
0.25
1430
763
763
774

0.5
0.03
1029
246
246
253
3958
1826

0.57
0.25
1637
1224
1224
1275

0.76
0.03
552
320
320
348
2871
3057

1.1
0.25
1103
1262
1262
1274

1.1
0.03
587
463
463
475
2105
3188

1
0.25
4875
4048
4048
4089

1.3
0.03
1833
487
487
531
1884
3059

c.n.c
c.n.c
c.n.c
c.n.c
c.n.c
c.n.c

0.52
0.03
165
77.3
77.3
107
9312
7134

Concentrations of 3a (RTC1) (mean ± SEM) in mouse (C57 Black, _) were determined following PO or IV administration at 10 mg/kg (n ¼ 3). See supporting information.
c.n.c ¼ could not calculate.
a
Oral and.
b
IV solutions were formulated in 10% DMSO, 10% cremaphor, 80% saline.

important for biological activity, with greater tolerance observed
for changes to the alkyl chain and thiophene heterocycle. Preliminary in vitro DMPK and in vivo PK studies are also described,
where encouraging results suggest that 3a (RTC1) does not act as a
P-gp substrate and should not provoke adverse drug-drug interactions. An initial in vitro metabolic stability study, using hepatocytes and microsomes, suggested that 3a (RTC1) would be readily
metabolised by the liver. Intravenous (IV) or oral administration of
3a (RTC1) to male C57BL/6 mice produced no observable toxic effects in our preliminary study. Following IV administration, 3a
(RTC1) had a short half-life of 0.45 h, showed high plasma clearance, and was distributed at high levels into all of the tissues
analysed apart from muscle. While 3a (RTC1) exhibited high mouse
and human serum protein binding, it had moderate bioavailability
(21.4%) suggesting the bound portion of 3a (RTC1) may act as a
reservoir or depot from which 3a (RTC1) is slowly released as the
unbound free form. The overall results suggest that aryl piperazines, and 3a (RTC1) in particular, have potential as efﬁcacious
agents for the treatment of diabetes.
4. Experimental section
4.1. Chemistry
4.1.1. General information
NMR spectra were recorded using Bruker Ascend 500 spectrometer at 293 K operating at 500 MHz for the 1H nucleus and
126 MHz for the 13C nucleus or a Bruker Advance 300 spectrometer
operating at 300 MHz for 1H nucleus and 75 MHz for 13C nucleus.
All chemical shifts were referenced relative to the relevant
deuterated solvent residual peaks or TMS. Chemical shifts were
given in ppm downﬁeld from the internal standard and coupling
constants were given in Hz. 13C NMR spectra were recorded with
complete proton decoupling. Microwave reactions were carried out
using a CEM Discover Microwave Synthesizer with a vertically
focused ﬂoor mounted infrared temperature sensor, external to the
microwave tube. The 10 mL reaction vessels used were supplied
from CEM and were made of borosilicate glass. Melting point analyses were carried out using a Stewart Scientiﬁc SMP11 melting
point apparatus and are uncorrected. High-resolution mass spectrometry (HRMS) was performed in Maynooth University (MU) and
the University of Bath (UoB). HRMS in MU was conducted on an
Agilent-LC 1200 Series coupled to a 6210 or 6530 Agilent Time-OfFlight (TOF) mass spectrometer equipped with an electrospray
source in both positive and negative (ESIþ/) modes. In UoB, HPLCESI-TOF analysis was conducted using an electrospray time-ofﬂight (MicrOTOF) mass spectrometer (Bruker Daltonik GmbH,
Bremen, Germany), which was coupled to an Agilent HPLC stack

(Agilent, Santa Clara, CA, United States) consisting of Agilent
G1312A binary pump with G1329A autosampler and G1316A column oven. Analyses were performed in ESI positive and negative
mode. Data processing was performed using the Compass Data
Analysis software scripts (Bruker Daltonik GmbH, Bremen, Germany). Infrared spectra were recorded on a Perkin Elmer Spectrum
100 FT-IR spectrophotometer using a smart endurance single
bounce diamond, attenuated total reﬂection (ATR) cell or potassium bromide (KBr) disks. Spectra were recorded in the region of
4000e600 cm1 and were obtained by the co-addition of 4 scans
with a resolution of 4 cm1. Scintillation counts were obtained
using a Wallac MicroBeta scintillation counter (Perkin Elmer). Reactions were monitored with thin layer chromatography (TLC) on
Merck Silica Gel F254 plates. Developed sheets were visualised
using a portable UVltec CV-006 lamp (l ¼ 254, 365 nm). Flash
column chromatography was performed using Merck Silica gel 60.
4.1.2. 1-(4-(Triﬂuoromethyl)phenyl)piperazine (2a)
1-Chloro-4-(triﬂuoromethyl)benzene (1.59 mL, 11.91 mmol) and
piperazine (2.00 g, 23.82 mmol) were dissolved in NMP (5 mL) and
heated at 200  C for 30 min in a microwave reactor. The reaction
mixture was puriﬁed using column chromatography (1:9,
MeOH:DCM) to give a white solid, 1.42 g (50%). Rf: 0.2 (9:1,
DCM:MeOH); IR (ATR): y (cm1) 3257, 2836, 1668, 1613, 1323, 1101,
1067; 1H NMR (500 MHz, CDCl3): d (ppm) 7.48 (d, J ¼ 8.8 Hz, 2H),
6.92 (d, J ¼ 8.8 Hz, 2H), 3.28e3.21 (m, 4H), 3.07e3.00 (m, 4H), 2.01
(bs, 1H); 1H NMR data matches literature data [32]; 13C NMR
(126 MHz, CDCl3): d (ppm) 153.7, 126.4 (q, J ¼ 3.8 Hz), 124.7 (q,
J ¼ 270.9 Hz), 120.6 (q, J ¼ 32.6 Hz), 114.6, 49.1, 45.9; 13C NMR data
matches literature data [32]; HRMS calcd for C11H14F3N2 [M þ H]þ
231.1104 found 231.1106.
4.1.3. 1-(p-Tolyl)piperazine (2c)
p-Toluidine (1.00 g, 9.34 mmol) and bis(2-chloroethyl)amine.HCl (1.66 g, 9.34 mmol) were dissolved in bis(2-methoxyethyl)
ether (20 mL) and heated at reﬂux for 16 h after which the reaction
mixture was allowed to cool to rt. Et2O was added until the precipitation of a brown solid was complete. The precipitate was
collected via vacuum ﬁltration and washed with Et2O (3  20 mL) to
give the HCl salt of compound 2c, which was then dissolved in a 5%
aqueous NaOH solution (10 mL) and stirred at rt for 4 h. The
aqueous layer was extracted with DCM (10 mL, followed be
3  10 mL) and the combined organic layers were dried over
MgSO4. The solvent was removed under reduced pressure and the
residue was puriﬁed using ﬂash chromatography to give a brown
solid, 221 mg (13%). Rf: 0.2 (1:9, MeOH:DCM); 1H NMR (300 MHz,
CDCl3): d (ppm) 7.07 (d, J ¼ 8.4 Hz, 2H), 6.83 (d, J ¼ 8.4 Hz, 2H),
3.14e3.13 (m, 4H), 3.08e3.05 (m, 4H), 2.26 (s, 3H); 1H NMR data
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matches literature data [33]; HRMS calcd for C11H17N2 [M þ H]þ
177.1385 found 177.1394.
4.1.4. 1-(2-Chloro-4-(triﬂuoromethyl)phenyl)piperazine (2i)
3-Chloro-4-ﬂuorobenzotriﬂuoride (100 mL, 0.75 mmol) and
piperazine (129 mg, 1.5 mmol) were dissolved in NMP (3 mL) and
heated at 200  C for 30 min in a microwave reactor. The reaction
mixture was puriﬁed using column chromatography (1:4,
MeOH:DCM) to give an orange oil, 124 mg (63%). Rf: 0.2 (1:9,
MeOH:DCM); 1H NMR (500 MHz, CDCl3): d (ppm) 7.61 (d, J ¼ 1.4 Hz,
1H), 7.47 (dd, J ¼ 8.4, 1.4 Hz, 1H), 7.08 (d, J ¼ 8.4 Hz, 1H), 3.10 (s, 8H),
2.78 (bs, 1H); 1H NMR data matches literature data [34]; 13C NMR
(126 MHz, CDCl3): d (ppm) 152.5, 128.6, 127.9 (q, J ¼ 3.8 Hz), 125.3
(q, J ¼ 33.3 Hz), 124.7 (q, J ¼ 3.9 Hz), 123.6 (q, J ¼ 272.2 Hz), 120.2,
51.9, 51.4, 50.9, 45.9; HRMS calcd for C11H13ClF3N2 [M þ H]þ 264.06;
found 265.0711.
4.1.5. 1-(2-Bromo-4-(triﬂuoromethyl)phenyl)piperazine (2j)
3-Bromo-4-chlorobenzotriﬂuoride (200 mL, 1.33 mmol) and
piperazine (229 mg, 2.66 mmol) were dissolved in NMP (2 mL) and
heated at 200  C for 30 min in a microwave reactor. Compound 4
was used without further puriﬁcation. Clear oil, 95 mg (23%, crude
yield). Rf: 0.2 (1:9, MeOH:DCM); 1H NMR (300 MHz, CDCl3):
d (ppm) 7.46 (d, J ¼ 7.8 Hz, 1H), 7.25e7.20 (m, 2H), 3.10 (m, 8H), 2.95
(bs, 1H); 1H NMR data matches literature data [35].
4.1.6. Method 1: General procedure for amide bond formation
Carboxylic acid, HOBt, TBTU, anhydrous NEt3 and anhydrous DMF
were placed in an oven-dried Schlenk tube under a N2 atmosphere.
The resulting solution was stirred at room temperature for 15 min. A
second Schlenk tube was prepared containing amine and anhydrous
DMF under a N2 atmosphere. The resulting solution was transferred,
via a cannula, to the ﬁrst Schlenk tube containing the carboxylic acid.
The solution was stirred under N2 overnight. DMF was removed
under reduced pressure and the resulting oil was acidiﬁed (pH ¼ 3)
using a 0.1 M aqueous HCl solution. The aqueous mixture was
extracted with DCM (20 mL, followed by 4  10 mL). The organic
combined layers were washed with a saturated aqueous solution of
Na2CO3 (3  20 mL) and brine (3  20 mL) and dried over MgSO4 and
the residue was puriﬁed using column chromatography.
4.1.7. Method 2: General procedure for amide bond formation
Carboxylic acid, HOBt, TBTU, NEt3 and DMF were placed in a
round-bottom ﬂask and stirred at room temperature for 15 min. A
second round-bottom ﬂask was prepared containing amine and
DMF. The resulting solution was transferred to the ﬁrst roundbottom ﬂask containing the carboxylic acid. The solution was stirred overnight. DMF was removed under reduced pressure and the
residue was puriﬁed using column chromatography.
4.1.8. 4-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)butan-1-one (3a)
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 4-(2-thienyl)butyric acid (50 mL,
0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.69 mmol) and DMF (3 mL) and
following the general procedure described in method 2 section
4.1.7 [10]. The reaction mixture was stirred at room temperature for
21 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2 EtOAc:n-hexane)
to give a white solid, 112 mg (86%). Rf: 0.5 (3:2, EtOAc:n-hexane); IR
(ATR): y (cm1) 2925, 2853, 1652, 1611, 1328, 1068; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.50 (d, J ¼ 8.5 Hz, 2H), 7.13 (d, J ¼ 4.9 Hz,
1H), 6.94e6.89 (m, 3H), 6.81 (bs, 1H), 3.77 (m 2H), 3.56 (m 2H),
3.31e3.17 (m, 4H), 2.93 (t, J ¼ 7.2 Hz, 2H), 2.40 (t, J ¼ 7.4 Hz, 2H),

11

2.13e2.0 (m, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 171.1, 152.9,
144.4, 126.9, 126.6 (q, J ¼ 3.7 Hz), 125.6 (q, J ¼ 271.3 Hz), 124.6, 123.3,
121.2 (q, J ¼ 32.8 Hz), 115.0, 48.3, 48.1, 45.0, 41.1, 32.0, 29.3, 27.0;
HRMS calcd for C19H21F3N2OSNa [M þ H]þ 405.1219 found
405.1228. Matches literature data [10,35].
4.1.9. 1-(4-Phenylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one
(3b)
Prepared from 1-phenylpiperazine (100 mL, 0.64 mmol) and 4(2-thienyl)butyric acid (84 mL, 0.58 mmol) using HOBt (86 mg,
0.64 mmol), TBTU (205 mg, 0.64 mmol), NEt3 (129 mL, 0.93 mmol)
and DMF (5 mL) and following the general procedure described in
method 2 section 4.1.7. The reaction mixture was stirred at room
temperature for 16.5 h. DMF was removed under reduced pressure
and the residue was puriﬁed using column chromatography (3:2,
EtOAc:n-hexane) to give a dark red oil, 142 mg (78%). Rf: 0.65 (3:2,
EtOAc:n-hexane); IR (ATR): y (cm1) 2915, 1639, 1597, 1227 (CeN);
1
H NMR (500 MHz, CDCl3): d (ppm) 7.30e7.23 (m, 2H), 7.11 (d,
J ¼ 5.1 Hz, 1H), 6.95e6.85 (m, 4H), 6.83e6.77 (m, 1H), 3.81e3.70 (m,
2H), 3.59e3.48 (m, 2H), 3.16e3.08 (m, 4H), 2.92 (t, J ¼ 7.3 Hz, 2H),
2.43 (t, J ¼ 7.3 Hz, 2H), 2.05 (p, J ¼ 7.3 Hz, 2H); 13C NMR (126 MHz,
CDCl3): d (ppm) 171.0, 151.0, 144.4, 129.2, 126.8, 124.5, 123.2, 120.5,
116.6, 49.7, 49.4, 45.4, 41.5, 32.0, 29.3, 27.0; HRMS calcd for
C18H23N2OS [M þ H]þ 315.1526 found 315.1531.
4.1.10. 4-(Thiophen-2-yl)-1-(4-(p-tolyl)piperazin-1-yl)butan-1-one
(3c)
Prepared from 1-(p-tolyl)piperazine 2c (221 mg, 1.25 mmol) and
4-(2-thienyl)butyric acid (166 mL, 1.13 mmol) using HOBt (168 mg,
1.25 mmol), TBTU (401 mg, 1.25 mmol), anhydrous NEt3 (253 mL,
1.82 mmol), and anhydrous DMF (5 mL) and following the general
procedure described in method 1 section 4.1.6 The reaction mixture
was stirred overnight at room temperature under a N2 atmosphere.
Puriﬁed using ﬂash chromatography (1:1 EtOAc:n-hexane) to give
an orange oil, 102 mg (24%). Rf: 0.3 (1:1, EtOAc:n-hexane); IR (neat):
y (cm1) 2917, 1642, 1439, 1232. 1H NMR (500 MHz, CDCl3): d (ppm)
7.12 (dd, J ¼ 5.2, 1.2 Hz, 1H), 7.09 (d, 2H, J ¼ 8.6 Hz), 6.92 (dd, J ¼ 5.2,
3.4 Hz, 1H), 6.83 (d, J ¼ 8.6 Hz, 2H), 6.81e6.80 (m, 1H), 3.78e3.76
(m, 2H), 3.56e3.54 (m, 2H), 3.09e3.07 (m, 4H), 2.92 (t, J ¼ 7.3 Hz,
2H), 2.40 (t, J ¼ 7.3 Hz, 2H), 2.28 (s, 3H), 2.08e2.02 (m, 2H). 13C NMR
(126 MHz, CDCl3): d (ppm) 171.0, 148.8, 144.4, 130.2, 129.7, 126.8,
124.5, 123.2, 117.0, 50.3, 50.0, 45.5, 41.5, 32.0, 29.3, 27.0, 20.4. HRMS
calcd for C19H25N2OS [M þ H]þ 329.1682 found 329.1687.
4.1.11. 1-(4-(4-Fluorophenyl)piperazin-1-yl)-4-(thiophen-2-yl)
butan-1-one (3d)
Prepared
from
1-(4-ﬂuorophenyl)piperazine
(100
mg,
0.55 mmol) and 4-(2-thienyl)butyric acid (73 mL, 0.50 mmol) using
HOBt (74 mg, 0.55 mmol), TBTU (177 mg, 0.55 mmol), anhydrous
NEt3 (123 mL, 0.80 mmol) and anhydrous DMF (5 mL) and following
the general procedure described in method 1 section 4.1.6. The reaction mixture was stirred at room temperature for 17 h under a N2
atmosphere. DMF was removed under reduced pressure and the
residue was puriﬁed using column chromatography (3:2, EtOAc:nhexane) to give an off-white solid, 119 mg (71%). Mp: 84e86  C; Rf:
0.6 (3:2, EtOAc:n-hexane); IR (KBr): y (cm1) 2824, 1651, 1511, 1437,
1334, 1203; 1H NMR (300 MHz, CDCl3): d (ppm) 7.12e7.10 (m, 1H),
7.03e6.76 (m, 6H), 3.78e3.74 (m, 2H), 3.56e3.50 (m, 2H), 3.05e3.02
(m, 4H), 2.92 (t, J ¼ 7.2 Hz, 2H), 2.40 (t, J ¼ 7.2 Hz, 2H), 2.09e1.99 (m,
2H). 13C NMR (75 MHz, CDCl3): d (ppm) 171.0, 157.6 (d, J ¼ 238.3 Hz),
147.6 (d, J ¼ 2.3 Hz), 144.4, 126.8, 124.5, 123.2, 118.5 (d, J ¼ 7.6 Hz),
115.7 (d, J ¼ 22.0 Hz), 50.8, 50.4, 45.5, 41.5, 32.0, 29.3, 27.0; Anal. calcd
for C18H21FN2OS C, 54.74; H, 4.84; N, 6.72; found C, 54.73; H, 4.60; N,
6.58; HRMS calcd for C18H22FN2OS [M þ H]þ 333.1431 found
333.1431.
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4.1.12. 1-(4-(4-Nitrophenyl)piperazin-1-yl)-4-(thiophen-2-yl)
butan-1-one (3e)
Prepared
from
1-(4-nitrophenyl)piperazine
(150
mg,
0.72 mmol) and 4-(2-thienyl)butyric acid (95 mL, 0.66 mmol) using
HOBt (97 mg, 0.72 mmol), TBTU (232 mg, 0.72 mmol), NEt3 (146 mL,
1.05 mmol), and DMF (6 mL) and following the general procedure
described in method 2 section 4.1.7. The reaction mixture was
stirred at room temperature for 22.5 h. DMF was removed under
reduced pressure and the residue was puriﬁed using column
chromatography (7:3, EtOAc:DCM) to give an orange solid, 199 mg
(84%). Mp: 120e121  C; Rf: 0.65 (7:3, EtOAc:DCM); IR (ATR): y
(cm1) 2857, 1648, 1599, 1321, 1163; 1H NMR (500 MHz, CDCl3):
d (ppm) 8.14 (dd, J ¼ 9.1, 1.4 Hz, 2H), 7.13 (dd, J ¼ 5.1, 1.1 Hz, 1H),
6.95e6.90 (m, 1H), 6.86e6.78 (m, 3H), 3.84e3.76 (m, 2H),
3.65e3.56 (m, 2H), 3.47e3.39 (m, 4H), 2.93 (t, J ¼ 7.2 Hz, 2H), 2.40
(t, J ¼ 7.2 Hz, 2H), 2.10e2.03 (m, 2H); 13C NMR (126 MHz, CDCl3)
d (ppm) 171.2, 154.4, 144.3, 139.1, 126.9, 126.0, 124.6, 123.3, 112.9,
47.0, 46.9, 44.7, 40.8, 31.9, 29.2, 26.8; HRMS calcd for
C18H21N3O3SNa [M þ Na]þ 382.1196 found 382.1212.
4.1.13. 1-(4-(4-Aminophenyl)piperazin-1-yl)-4-(thiophen-2-yl)
butan-1-one (3f)
Prepared from 1-(4-(4-nitrophenyl)piperazin-1-yl)-4-(thiophen-2-yl)butan-1-one 3e (143 mg, 0.39 mmol) dissolved in MeOH
(10 mL) in a round bottom ﬂask with PtO2 (20 mg, 0.08 mmol). The
resulting mixture was degassed and purged with H2 (x3), stirred
vigorously at room temperature for 16.5 h under an atmosphere of
H2 gas and monitored by TLC (7:1, EtOAc:DCM). The reaction
mixture was passed through a bed of Celite and the ﬁltrate was
concentrated under reduced pressure. The residue was puriﬁed
using column chromatography (7:1, EtOAc:DCM) to give a brown
oil, 75 mg (57%). Rf: 0.4 (7:1, EtOAc:DCM); IR (ATR): y (cm1) 3337,
2815, 1638, 1510, 1223; 1H NMR (500 MHz, CDCl3): d (ppm) 7.12 (dd,
J ¼ 5.1, 1.2 Hz, 1H), 6.92 (dd, J ¼ 5.1, 3.4 Hz, 1H), 6.82e6.77 (m, 3H,
H2), 6.67e6.63 (m, 2H), 3.77e3.74 (m, 2H), 3.56e3.52 (m, 2H),
2.99e2.90 (m, 6H), 2.42e2.38 (m, 2H), 2.08e2.01 (m, 2H); 13C NMR
(126 MHz, CDCl3): d (ppm) 171.0, 144.5, 144.0, 140.9, 126.8, 124.5,
123.2, 119.3, 116.2, 51.6, 51.2, 45.7, 41.7, 32.1, 29.3, 27.1; HRMS calcd
for C18H24N3OS [M þ H]þ 331.1664 found: 331.1669.
4.1.14. 4-(Thiophen-2-yl)-1-(4-(2-(triﬂuoromethyl)phenyl)
piperazin-1-yl)butan-1-one (3g)
Prepared from 1-(2-(triﬂuoromethyl)phenyl)piperazine (83 mL,
0.43 mmol) and 4-(2-thienyl)butyric acid (57 mL, 0.39 mmol) using
HOBt (58 mg, 0.43 mmol), TBTU (139 mg, 0.43 mmol), NEt3 (60 mL,
0.62 mmol) and DMF (4 mL) and following the general procedure
described in method 2 section 4.1.7. The reaction mixture was
stirred at room temperature for 22 h. DMF was removed under
reduced pressure and the residue was puriﬁed using column
chromatography (3:2, EtOAc:n-hexane) to give a colourless oil,
122 mg (82%). Rf: 0.74 (3:2, EtOAc:n-hexane); IR (ATR): y (cm1)
2916, 1642, 1312, 1107 cm1; 1H NMR (500 MHz, CDCl3): d (ppm)
7.64 (d, J ¼ 7.9 Hz, 1H), 7.56e7.48 (m, 1H), 7.33e7.21 (m, 2H), 7.12
(dd, J ¼ 5.1, 1.1 Hz, 1H), 6.92 (dd, J ¼ 5.1, 3.4 Hz, 1H), 6.82 (dd, J ¼ 3.3,
0.9 Hz, 1H), 3.76 (bs, 2H), 3.59e3.48 (m, 2H), 2.97e2.82 (m, 6H),
2.41 (t, J ¼ 7.5 Hz, 2H), 2.06 (p, J ¼ 7.4 Hz, 2H); 13C NMR (126 MHz,
CDCl3): d (ppm) 171.0, 151.7 (d, J ¼ 1.1 Hz), 144.4, 132.8, 127.4 (q,
J ¼ 28.7 Hz), 127.2 (q, J ¼ 5.4 Hz), 126.7, 125.3, 124.4, 124.0, 123.9 (q,
J ¼ 273.7 Hz), 123.1, 53.7, 53.0, 46.0, 42.0, 32.1, 29.3, 27.0; HRMS
calcd for C19H22F3N2OS [M þ H]þ, 383.1399 found 383.1406.
4.1.15. 1-(4-(3,5-bis(Triﬂuoromethyl)phenyl)piperazin-1-yl)-4(thiophen-2-yl)butan-1-one (3h)
Prepared from 1-(3,5-bis(triﬂuoromethyl)phenyl)piperazine
(194 mg, 0.65 mmol) and 4-(2-thienyl)butyric acid (85 mL,

0.58 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (207 mg,
0.65 mmol), NEt3 (129 mL, 0.92 mmol) and DMF (5 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
14.5 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2, EtOAc:n-hexane)
to give a clear oil, 223 mg (86%). Mp: 46e49  C; Rf: 0.78 (3:2,
EtOAc:n-hexane); IR (ATR): y (cm1) 2835, 1655, 1273, 1120; 1H
NMR (500 MHz, CDCl3): d (ppm) 7.33 (s, 1H), 7.24 (s, 2H), 7.12 (dd,
J ¼ 5.0 Hz), 6.96e6.89 (m, 1H), 6.81 (s, 1H), 3.86e3.76 (m, 2H),
3.65e3.55 (m, 2H), 3.34e3.21 (m, 4H), 2.93 (t, J ¼ 7.2 Hz, 2H), 2.41
(t, J ¼ 7.2 Hz, 2H), 2.11e2.02 (m, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 171.1, 151.3, 144.3, 132.5 (q, J ¼ 32.8 Hz), 126.8, 124.6, 123.5
(q, J ¼ 273.3 Hz), 123.2, 115.1 (m), 112.7 (m), 48.4, 48.3, 44.9, 41.0,
31.9, 29.2, 26.9; Anal. calcd for C20H20F6N2OS C, 53.33; H, 4.48; N,
6.22; found C, 53.41; H, 4.25; N, 6.27; HRMS calcd for
C20H20F6N2OSNa [M þ Na]þ 473.1093 found 473.1107.
4.1.16. 1-(4-(2-Chloro-4-(triﬂuoromethyl)phenyl)piperazin-1-yl)-4(thiophen-2-yl)butan-1-one (3i). [35]
Prepared from 1-(2-chloro-4-(triﬂuoromethyl)phenyl)piperazine 2i (90 mg, 0.34 mmol) and 4-(2-thienyl)butyric acid (46 mL,
0.32 mmol) using HOBt (47 mg, 0.34 mmol), TBTU (111 mg,
0.34 mmol), NEt3 (47 mL, 0.51 mmol) and DMF (3 mL) and following
the general procedure described in method 2 section 4.1.7. The
reaction mixture was stirred at room temperature for 19 h. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (3:2, EtOAc:Pet. ether (40e60  C))
to give an oil, 111 mg (83%). Mp: 84e86  C; Rf: 0.7 (3:2, EtOAc:Pet.
ether (40e60  C)); IR (ATR): y (cm1) 2823, 1624, 1325, 1111, 694; 1H
NMR (500 MHz, CDCl3): d (ppm) 7.65e7.62 (m, 1H), 7.48 (dd, J ¼ 8.4,
1.7 Hz, 1H), 7.13 (dd, J ¼ 5.1, 1.0 Hz, 1H), 7.05 (d, J ¼ 8.4 Hz, 1H),
6.95e6.91 (m, 1H), 6.84e6.79 (m, 1H), 3.86e3.76 (m, 2H),
3.64e3.56 (m, 2H), 3.09e3.02 (m, 4H), 2.93 (t, J ¼ 7.3 Hz, 2H), 2.42
(t, J ¼ 7.5 Hz, 2H), 2.06 (p, J ¼ 7.4 Hz, 2H); 13C NMR (126 MHz,
CDCl3): d (ppm) 171.2, 151.6, 144.4, 128.8, 128.0 (q, J ¼ 3.8 Hz), 126.8,
126.0 (q, J ¼ 33.4 Hz), 124.9 (q, J ¼ 3.7 Hz), 124.6, 123.5 (q,
J ¼ 272.2 Hz), 123.3, 120.4, 51.2, 50.7, 45.6, 41.6, 32.1, 29.3, 27.0; Anal.
calcd for C19H20F3N2OSCl C, 54.74; H, 4.84; N, 6.72; found C, 54.73;
H, 4.60; N, 6.58; HRMS calcd for C19H20F3N2OSClNa [M þ Na]þ
439.0829 found 439.085.
4.1.17. 1-(4-(2-Bromo-4-(triﬂuoromethyl)phenyl)piperazin-1-yl)-4(thiophen-2-yl)butan-1-one (3j) [35]
Prepared from 1-(2-bromo-4-(triﬂuoromethyl)phenyl)piperazine 2j (95 mg, 0.30 mmol) and 4-(2-thienyl)butyric acid (41 mL,
0.28 mmol) using HOBt (41 mg, 0.30 mmol), TBTU (98 mg,
0.30 mmol), anhydrous NEt3 (62 mL, 0.44 mmol) and anhydrous
DMF (2 mL) and following the general procedure described in
method 1 section 4.1.6. The reaction mixture was stirred at room
temperature for 21 h under N2 atmosphere. DMF was removed
under reduced pressure and the residue was puriﬁed using column
chromatography (1:1, EtOAc:Pet. ether (40e60  C)) to give a clear
oil, 60 mg (50%). Rf: 0.8 (1:1 EtOAc:Pet. ether (40e60  C)); IR (neat):
y (cm1) 2914, 1645, 1605, 1432, 1324, 1122, 680; 1H NMR (500 MHz,
CDCl3): d (ppm) 7.49 (dd, J ¼ 8.3, 0.6 Hz, 1H), 7.28e7.24 (m, 1H),
7.22e7.20 (m, 1H), 7.14 (dd, J ¼ 5.1, 1.2 Hz, 1H), 6.93 (dd, J ¼ 5.1,
3.4 Hz, 1H), 6.84e6.80 (m, 1H), 3.86e3.79 (m, 2H), 3.63e3.58 (m,
2H), 3.07e3.02 (m, 4H), 2.94 (td, J ¼ 7.3, 0.5 Hz, 2H), 2.45e2.38 (m,
2H), 2.11e2.03 (m, 2H). 13C NMR (126 MHz, CDCl3): d (ppm) 171.3,
149.2, 144.4, 132.6 (q, J ¼ 1.26 Hz), 131.2, 130.2 (q, J ¼ 32.8 Hz), 126.8,
124.6, 123.7 (q, J ¼ 272.9 Hz), 123.2, 120.8 (q, J ¼ 3.77 Hz), 117.4 (q,
J ¼ 3.7 Hz), 51.3, 51.0, 45.6, 41.7, 32.1, 29.3, 27.0; HRMS calcd for
C19H20BrF3N2OSK [M þ K]þ 499.0063 found 499.0079.
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4.1.18. 4-(Thiophen-3-yl)-1-(4-(5-(triﬂuoromethyl)pyridin-2-yl)
piperazin-1-yl)butan-1-one (5a) [35]
Prepared from 1-(5-(triﬂuoromethyl)pyridin-2-yl)piperazine
(99 mg, 0.43 mmol) and 4-(2-thienyl)butyric acid (50 mL,
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.69 mmol) and DMF (3 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
20 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2 EtOAc:n-hexane)
to give a white solid, 119 mg (91%). Mp: 107e109  C; Rf: 0.5 (3:2,
EtOAc:n-hexane); IR (ATR): y (cm1) 2912, 1645, 1609, 1415, 1318,
1106; 1H NMR (500 MHz, CDCl3): d (ppm) 8.41 (s, 1H), 7.66 (dd,
J ¼ 9.0 Hz, J ¼ 2.2 Hz, 1H), 7.14e7.10 (m, 1H), 6.94e6.91 (m, 1H),
6.82e6.80 (m, 1H), 6.64 (d, J ¼ 9.0 Hz, 1H), 3.79e3.68 (m, 4H),
3.66e3.56 (m, 2H), 3.56e3.49 (m, 2H), 2.93 (t, J ¼ 7.4 Hz, 2H), 2.41
(t, J ¼ 7.4, 2H), 2.06 (p, J ¼ 7.4 Hz, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 171.3, 160.1, 145.8 (q, J ¼ 4.3 Hz), 144.3, 134.7 (q, J ¼ 3.2 Hz),
126.8, 124.6, 124.5 (q, J ¼ 270.9 Hz), 123.2, 115.9 (q, J ¼ 33.1 Hz),
105.7, 45.0, 44.7, 44.4, 41.0, 32.0, 29.3, 26.9; Anal. calcd for
C18H20F3N3OS C, 56.38; H, 5.26; N, 10.96; found C, 56.64; H,4.95; N,
10.89; HRMS calcd for C18H21F3N3OS [M þ H]þ 384.1352 found
384.1355.
4.1.19. 1-(4-(6-Chloro-5-(triﬂuoromethyl)pyridin-2-yl)piperazin-1yl)-4-(thiophen-2-yl)butan-1-one (5b) [35]
Prepared from 1-(6-chloro-5-(triﬂuoromethyl)pyridin-2-yl)
piperazine (218 mg, 0.816 mmol) and 4-(2-thienyl)butyric acid
(100 mL, 0.68 mmol) using HOBt (110 mg, 0.82 mmol), TBTU
(262 mg, 0.82 mmol), anhydrous NEt3 (152 mL, 1.08 mmol) and
anhydrous DMF (5 mL) and following the general procedure
described in method 1 section 4.1.6. The reaction mixture was
stirred at room temperature for 20 h under a N2 atmosphere. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (3:2, EtOAc:Pet. ether (40e60  C))
to give a beige solid, 192 mg (68%). Mp: 62e64  C; Rf: 0.48 (3:2,
EtOAc:Pet. ether (40e60  C)); IR (KBr): y (cm1) 2904, 1678, 1641,
1416, 1321, 1120, 698; 1H NMR (500 MHz, CDCl3): d (ppm) 7.70 (d,
J ¼ 8.8 Hz, 1H), 7.13 (dd, J ¼ 5.1, 1.2 Hz, 1H), 6.92 (dd, J ¼ 5.1, 3.4 Hz,
1H), 6.84e6.77 (m, 1H), 6.48 (d, J ¼ 8.7 Hz, 1H), 3.79e3.66 (m, 4H),
3.64e3.45 (m, 4H), 2.93 (t, J ¼ 7.5 Hz, 2H), 2.45e2.35 (m, 2H),
2.10e2.02 (m, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 171.3, 159.0,
147.7, 144.3, 137.8 (q, J ¼ 4.5 Hz), 126.9, 124.6, 123.3, 123.2 (q,
J ¼ 271.0 Hz), 113.0 (q, J ¼ 33.6 Hz), 103.3, 44.8, 44.6, 44.2, 40.8, 32.0,
29.2, 26.9; HRMS calcd for C18H20ClF3N3OSCl [M þ H]þ, 418.0962
found 418.0953.
4.1.20. 1-(4-(3-Chloro-5-(triﬂuoromethyl)pyridin-2-yl)piperazin-1yl)-4-(thiophen-2-yl)butan-1-one (5c) [35]
Prepared from 1-(3-chloro-5-(triﬂuoromethyl)pyridin-2-yl)
piperazine (114 mg, 0.43 mol) and 4-(2-thienyl)butyric acid (50 mL,
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.69 mmol) and DMF (3 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
19 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2, EtOAc:n-hexane)
to give a solid, 123 mg (87%). Mp: 52e54  C; Rf: 0.78 (3:2, EtOAc:nhexane); IR (ATR): y (cm1) 3036, 2852, 1646, 1600, 1438, 1317, 1117,
847; 1H NMR (500 MHz, CDCl3): d (ppm) 8.40 (s, 1H), 7.79 (s, 1H),
7.14e7.10 (m, 1H), 6.95e6.89 (m, 1H), 6.83e6.78 (m, 1H), 3.81e3.74
(m, 2H), 3.60e3.53 (m, 2H), 3.51e3.44 (m, 4H), 2.93 (t, J ¼ 7.2 Hz,
2H), 2.41 (t, J ¼ 7.4 Hz, 2H), 2.06 (p, J ¼ 7.3 Hz, 2H); 13C NMR
(126 MHz, CDCl3): d (ppm) 171.2, 159.6, 144.4, 143.0 (q, J ¼ 4.2 Hz),
136.1 (q, J ¼ 3.3 Hz), 126.8, 124.5, 123.2 (q, J ¼ 272.3 Hz), 123.2, 121.1,
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120.6 (q, J ¼ 33.5 Hz), 48.6, 45.2, 41.3, 32.0, 29.3, 27.0; Anal. calcd for
C18H19F3N3OSCl C, 51.73; H, 4.58; N, 10.06; found C, 52.17; H, 4.66;
N, 9.89; HRMS calcd for C18H20F3N3OSCl [M þ H]þ 418.0971 found
418.0963.
4.1.21. 1-(4-Cyclohexylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1one (5d)
Prepared from 1-cyclohexylpiperazine (150 mg, 0.89 mmol) and
4-(2-thienyl)butyric acid (118 mL, 0.81 mmol) using HOBt (120 mg,
0.89 mmol), TBTU (285 mg, 0.89 mmol), NEt3 (180 mL, 1.29 mmol)
and DCM (6 mL) and following the general procedure described in
method 2 section 4.1.7. The reaction mixture was stirred at room
temperature for 17.5 h. DCM was removed under reduced pressure
and the residue was puriﬁed using column chromatography (9:1,
DCM:MeOH) to give a red solid, 213 mg (82%). Mp: 33e35  C; Rf:
0.56 (9:1, DCM:MeOH); IR (ATR): y (cm1) 2928, 2851, 1632, 1445;
1
H NMR (500 MHz, CDCl3): d (ppm) 7.11 (dd, J ¼ 5.1, 1.0 Hz, 1H), 6.91
(dd, J ¼ 5.1, 3.4 Hz, 1H), 6.79 (dd, J ¼ 3.4, 1.0 Hz, 1H), 3.70e3.55 (m,
2H), 3.45e3.31 (m, 2H), 2.90 (t, J ¼ 7.3 Hz, 2H), 2.67e2.40 (m, 4H),
2.40e2.32 (m, 2H), 2.32e2.25 (m, 1H), 2.07e1.96 (m, 2H), 1.90e1.73
(m, 4H), 1.69e1.56 (m, 1H), 1.31e1.14 (m, 4H), 1.14e1.04 (m, 1H); 13C
NMR (126 MHz, CDCl3): d (ppm) 170.8, 144.5, 126.8, 124.6, 123.1,
63.6, 49.3, 48.7, 45.9, 41.9, 32.0, 29.3, 28.8, 27.1, 26.2, 25.8; HRMS
calcd for C18H29N2OS [M þ H]þ 321.1995 found 321.2005.
4.1.22. 1-(4-Methylpiperazin-1-yl)-4-(thiophen-2-yl)butan-1-one
(5e)
Prepared from 1-methylpiperazine (71 mL, 0.65 mmol) and 4-(2thienyl)butyric acid (85 mL, 0.59 mmol) using HOBt (87 mg,
0.65 mmol), TBTU (207 mg, 0.65 mmol), NEt3 (90 mL, 0.94 mmol),
and DCM (4 mL), and following the general procedure described in
method 2 section 4.1.7. The reaction mixture was stirred at room
temperature for 18 h. DCM was removed under reduced pressure
and the residue was puriﬁed using column chromatography (3:2,
EtOAc:n-hexane) to give a yellow oil, 104 mg (70%). Rf: 0.56 (100%
DCM); IR (ATR): y (cm1) 2936, 2792, 1635, 1435, 1289; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.11 (dd, J ¼ 5.1, 1.2 Hz, 1H), 6.91 (dd,
J ¼ 5.1, 3.4 Hz, 1H), 6.80 (ddd, J ¼ 3.4, 2.1, 1.2 Hz, 1H), 3.65e3.61 (m,
2H), 3.43e3.39 (m, 2H), 2.90 (t, J ¼ 7.3 Hz, 2H), 2.38e2.33 (m, 6H),
2.29 (s, 3H), 2.02 (p, J ¼ 7.4 Hz, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 170.9, 144.5, 126.8, 124.5, 123.1, 55.2, 54.7, 46.0, 45.4, 41.5,
32.0, 29.3, 27.0; HRMS calcd for C13H21N2OS [M þ H]þ 253.1369
found 253.1367.
4.1.23. 4-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperidin-1-yl)butan-1-one (7a) [35]
Prepared from 4-(4-(triﬂuoromethyl)phenyl)piperidine.HCl
(100 mg, 0.38 mmol) and 4-(2-thienyl)butyric acid (50 mL,
0.34 mmol) using HOBt (51 mg, 0.38 mmol), TBTU (122 mg,
0.38 mmol), NEt3 (55 mL, 0.54 mmol) and DMF (2 mL) and following
the general procedure described in method 2 section 4.1.7. The
reaction mixture was stirred for 22 h at room temperature. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (3:2, EtOAc:n-hexane) to give an
off-white solid, 87 mg (67%). Mp: 48e49  C; Rf: 0.7 (3:2, EtOAc:nhexane); IR (ATR): y (cm1) 2850, 1644, 1323, 1112; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.56 (d, J ¼ 8.0 Hz, 2H), 7.30 (d,
J ¼ 8.0 Hz, 2H), 7.12 (d, J ¼ 5.1 Hz, 1H), 6.97e6.87 (m, 1H), 6.83e6.79
(m, 1H), 4.82 (d, J ¼ 13.2 Hz, 1H), 3.92 (d, J ¼ 13.5 Hz, 1H), 3.10 (t,
J ¼ 12.9 Hz, 1H), 2.93 (t, J ¼ 7.3 Hz, 2H), 2.85e2.74 (m, 1H), 2.63 (t,
J ¼ 12.7 Hz, 1H), 2.41 (t, J ¼ 7.4 Hz, 2H), 2.06 (p, J ¼ 7.4 Hz, 2H),
1.93e1.84 (m, 2H), 1.68e1.52 (m, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 170.9, 149.2, 144.5, 128.9 (q, J ¼ 32.5 Hz), 127.1, 126.8, 125.6
(q, J ¼ 3.8 Hz), 124.5, 124.2 (q, J ¼ 272.3 Hz), 123.1, 46.0, 42.7, 42.2,
33.7, 32.6, 32.2, 29.4, 27.1; HRMS calcd for C20H22F3NOSNa [M þ
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Na]þ 404.1266 found 404.1279.
4.1.24. 4-(Thiophen-2-yl)-N’-(4-(triﬂuoromethyl)phenyl)butane
hydrazide (7b)
Prepared from (4-(triﬂuoromethyl)phenyl)hydrazine (195 mg,
1.11 mmol) and 4-(2-thienyl)butyric acid (149 mL, 1.03 mmol) using
HOBt (149 mg, 1.11 mmol), TBTU (356 mg, 1.11 mmol), anhydrous
NEt3 (231 mL, 1.66 mmol) and anhydrous DMF (8 mL) and following
the general procedure described in method 1 section 4.1.6. The
reaction mixture was stirred at room temperature for 20 h under a
N2 atmosphere. DMF was removed under reduced pressure and the
residue was puriﬁed using column chromatography (elution
gradient 1:1 EtOAc:n-hexane to 3:2 EtOAc:n-hexane) to give an offwhite solid, 235 mg (69%). Mp: 110e112  C; Rf: 0.3 (1:1, EtOAc:nhexane); IR (KBr): y (cm1) 3309, 2963, 1639, 1614, 1333, 1104; 1H
NMR (500 MHz, DMSO‑d6): d (pm) 9.82 (d, J ¼ 1.4 Hz, 1H), 8.39 (s,
1H), 7.47 (d, J ¼ 8.6 Hz, 2H), 7.34 (dd, J ¼ 5.1, 1.0 Hz, 1H), 6.97 (dd,
J ¼ 5.1, 3.4 Hz, 1H), 6.88 (m, 1H), 6.79 (d, J ¼ 8.5 Hz, 2H), 2.83 (t,
J ¼ 7.6 Hz, 2H), 2.26 (t, J ¼ 7.4 Hz, 2H), 1.95e1.85 (m, 2H); 13C NMR
(126 MHz, DMSO‑d6): d (ppm) 172.2, 153.0, 144.5, 127.5, 126.6 (q,
J ¼ 3.8 Hz), 126.1 (q, J ¼ 294.2 Hz), 125.1, 124.1, 118.5 (q, J ¼ 31.9 Hz),
111.8, 32.9, 29.1, 27.7; Anal. calcd for C15H15F3N2OS C, 54.87; H, 4.60;
N, 8.53; found C, 54.44; H, 4.39; N, 8.09; HRMS calcd for
C15H16F3N2OS [M þ H]þ 330.0975 found 330.096.
4.1.25. 4-(Thiophen-2-yl)-N-(4-(triﬂuoromethyl)phenyl)
butanamide (7c)
Prepared from 4-(triﬂuoromethyl)aniline (69 mg, 0.43 mmol)
and 4-(thiophen-2-yl)butanoic acid (50 mL, 0.34 mmol) using HOBt
(58 mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), NEt3 (100 mL,
0.51 mmol) and DCM (6 mL) and following the general procedure
described in method 2 section 4.1.7. The reaction mixture was
stirred at room temperature for 20 h. DCM was removed under
reduced pressure and the residue was puriﬁed using column
chromatography (3:2, EtOAc:n-hexane) to give a white solid, 96 mg
(90%). Rf: 0.6 (3:2, EtOAc:n-hexane); IR (ATR): y (cm1) 3304, 2926,
1670, 1514, 1319, 1125; 1H NMR (500 MHz, CDCl3): d (ppm) 7.62 (d,
J ¼ 8.6 Hz, 2H), 7.56 (d, J ¼ 8.6 Hz, 2H), 7.29 (bs, 1H), 7.14 (ddd,
J ¼ 5.1, 1.2, 0.5 Hz, 1H), 6.93 (dd, J ¼ 5.1, 3.4 Hz, 1H), 6.81 (dd, J ¼ 2.2,
1.1 Hz, 1H), 2.94 (t, J ¼ 7.2 Hz, 2H), 2.42 (t, J ¼ 7.4 Hz, 2H), 2.12 (p,
J ¼ 7.2 Hz, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 171.0, 143.8,
140.8, 126.9, 126.3 (q, J ¼ 3.8 Hz), 126.1 (q, J ¼ 33.0 Hz), 124.8, 124.1
(q, J ¼ 272.1 Hz), 123.4, 119.3, 36.4, 29.0, 27.0; HRMS calcd for
C15H14NOSNa [M þ H]þ 336.1393 found 336.1393.
4.1.26. 3-(Thiophen-2-ylthio)propanoic acid (8f)
Thienyl-2-thiol (48 mL, 0.52 mmol), 3-bromopropanoic acid
(80 mg, 0.52 mmol) and NaHCO3 (130 mg, 1.56 mmol) were heated
at reﬂux in EtOH (2 mL). After 5 h the reaction mixture was allowed
to cool to room temperature and the EtOH was removed under
reduced pressure. The residue was dissolved in H2O (2 mL) and
washed with Et2O (4  10 mL). The aqueous layer was acidiﬁed to
pH ¼ 6 with 0.1 M aqueous HCl and extracted with Et2O
(4  10 mL). The combined organic layers were concentrated under
reduced pressure and the residue was puriﬁed using column
chromatography (1:9, MeOH:DCM) to give a clear oil, 83 mg (85%).
Rf: 0.3 (1:9, MeOH:DCM); 1H NMR (300 MHz, CDCl3): d (ppm) 10.86
(br s, 1H), 7.37 (dd, J ¼ 5.1, 1.2 Hz, 1H), 7.16 (dd, J ¼ 2.4, 1.2 Hz, 1H),
6.97e6.99 (m, 1H), 2.97 (t, J ¼ 7.2 Hz, 2H), 2.64 (t, J ¼ 7.2 Hz, 2H); 1H
NMR data matches literature data [31]; HRMS calcd for C7H9O2S2
[M þ H]þ: 189.0038 found 189.0040.
4.1.27. Thiophen-2-yl (4-(4-(triﬂuoromethyl)phenyl)piperazin-1-yl)
methanone (9a)
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a

(76 mg, 0.33 mmol) and thiophene-2-carboxylic acid (38 mg,
0.30 mmol) using HOBt (45 mg, 0.33 mol), TBTU (107 mg,
0.33 mmol), NEt3 (75 mL, 0.48 mmol) and DMF (4 mL) and following
the general procedure described in method 2 section 4.1.7. The
reaction mixture was stirred for 21 h at room temperature. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (1:1, EtOAc:Pet. ether (40e60  C)) to
give a solid, 70 mg (69%). Mp: 126e130  C; Rf: 0.6 (1:1, EtOAc:Pet.ether (40e60  C)); IR (ATR): y (cm1) 2838, 1606, 1334, 1096; 1H
NMR (500 MHz, CDCl3): d (ppm) 7.55e7.45 (m, 3H), 7.35 (d,
J ¼ 3.2 Hz, 1H), 7.13e7.02 (m, 1H), 6.93 (d, J ¼ 8.6 Hz, 2H), 3.98e3.86
(m, 4H), 3.42e3.27 (m, 4H); 13C NMR (126 MHz, CDCl3) d (ppm)
163.7, 152.8, 136.6, 129.1, 129.0, 126.8, 126.5 (q, J ¼ 3.8 Hz), 124.5 (q,
J ¼ 271.3 Hz), 121.3 (q, J ¼ 32.8 Hz), 114.9, 48.2; Anal. calcd for
C16H15F3N2OS C, 56.46; H, 4.44; N, 8.23; found C, 56.72; H, 4.62; N,
8.42; HRMS calcd for C16H15F3N2OSNa [M þ Na]þ 363.0749 found
363.0762.
4.1.28. 2-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)ethanone (9b) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 2-(thiophen-2-yl)acetic acid (48 mg,
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg,
0.43 mmol), NEt3 (87 mL, 0.63 mmol), DMF (4 mL) and following the
general procedure described in method 2 section 4.1.7. The reaction
mixture was stirred at room temperature for 21 h. Puriﬁed using
column chromatography (3:2, EtOAc:n-hexane) to give an orange
solid, 98 mg (82%). ]. Rf: 0.9 (3:2, EtOAc:n-hexane); IR (ATR): y
(cm1) 2826, 1614, 1409, 1336, 1229, 1101; 1H NMR (500 MHz,
CDCl3): d (ppm) 7.49 (d, J ¼ 8.7 Hz, 2H), 7.21 (dd, J ¼ 5.1 Hz,
J ¼ 1.2 Hz, 1H), 6.97e6.88 (m, 4H), 3.96 (s, 2H), 3.84e3.78 (m, 2H),
3.72e3.64 (m, 2H), 3.29e3.23 (m, 2H), 3.21e3.12 (m, 2H); 13C NMR
(126 MHz, CDCl3): d (ppm) 168.5, 152.8, 136.2, 127.0, 126.5 (q,
J ¼ 3.3 Hz), 126.1, 124.9, 124.6 (q, J ¼ 271.3 Hz), 121.4 (q, J ¼ 32.8 Hz),
115.0, 48.2, 47.9, 45.8, 41.5, 35.2; HRMS calcd for C17H17F3N2O2SNa
[M þ Na]þ 377.0906 found 377.0915.
4.1.29. 3-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)propan-1-one (9c) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(81 mg, 0.35 mmol) and 3-(thiophen-2-yl)propanoic acid (50 mg,
0.32 mmol) using HOBt (47 mg, 0.35 mmol), TBTU (113 mg,
0.35 mmol), anhydrous NEt3 (71 mL, 0.51 mmol) and anhydrous
DMF (5 mL) and following the general procedure described in
method 1 section 4.1.6. The reaction mixture was stirred at room
temperature for 16 h under a N2 atmosphere. DMF was removed
under reduced pressure and the residue was puriﬁed using column
chromatography (3:2, EtOAc:n-hexane) to give an orange solid,
52 mg (44%). Mp: 50e54  C; Rf: 0.5 (3:2, EtOAc:n-hexane); IR (KBr):
y (cm1) 2826, 1632, 1615, 1441, 1338, 1229; 1H NMR (300 MHz,
CDCl3): d (ppm) 7.49 (d, J ¼ 8.5 Hz, 2H), 7.12 (dd, J ¼ 5.1 Hz,
J ¼ 1.2 Hz), 6.95e6.87 (m, 3H), 6.87e6.82 (m, 1H), 3.80e3.77 (m,
2H), 3.59e3.56 (m, 2H), 3.25e3.17 (m, 6H, 4H), 2.79e2.65 (m, 2H);
13
C NMR (75 MHz, CDCl3): d (ppm) 170.2, 152.8, 143.6, 126.9, 126.5
(q, J ¼ 3.3 Hz), 124.8, 124.5 (q, J ¼ 269.7 Hz), 123.5, 121.3 (q,
J ¼ 32.4 Hz), 115.0, 48.2, 48.0, 45.0, 41.2, 35.1, 25.5; HRMS calcd for
C18H20F3N2OS [M þ H]þ 369.1243 found: 369.1238.
4.1.30. 5-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)pentan-1-one (9d) [35]
Prepared from 5-(thiophen-2-yl)pentanoic acid (72 mg,
0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg,
0.43 mmol), anhydrous NEt3 (86 mL, 0.62 mmol), and anhydrous
DMF (4 mL) in an oven-dried Schlenk tube under a N2 atmosphere.
The resulting solution was stirred at room temperature for 15 min.
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A second Schlenk tube was prepared containing 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a (100 mg, 0.43 mmol) and DMF
(4 mL) under a N2 atmosphere. The resulting solution was transferred, via a cannula, to the ﬁrst Schlenk tube containing the carboxylic acid. The reaction mixture was stirred at room temperature
for 18 h under a N2 atmosphere. The DMF was removed under
reduced pressure. The resulting oil was acidiﬁed (pH ¼ 3) using a
0.1 M aqueous HCl solution and puriﬁed using column chromatography (3:2, EtOAc:n-hexane) to give a solid, 113 mg (73%). Mp:
46e48  C; Rf: 0.66 (3:2, EtOAc:n-hexane); IR (KBr): y (cm1) 2862,
1634, 1612, 1438, 1326, 1107; 1H NMR (500 MHz, CDCl3): d (ppm)
7.50 (d, J ¼ 8.8 Hz, 2H), 7.09 (dd, J ¼ 5.1, 1.2 Hz, 1H), 6.94e6.86 (m,
3H), 6.81e6.74 (m, 1H), 3.82e3.70 (m, 2H), 3.66e3.53 (m, 2H),
3.27e3.20 (m, 4H), 2.87 (t, J ¼ 6.7 Hz, 2H), 2.39 (t, J ¼ 7.0 Hz, 2H),
1.81e1.68 (m, 4H); 13C NMR (126 MHz, CDCl3): d (ppm) 171.4, 152.9,
145.0, 126.7, 126.5 (q, J ¼ 3.8 Hz), 124.6 (q, J ¼ 271.3 Hz), 124.2, 123.0,
121.3 (q, J ¼ 32.9 Hz), 115.0, 48.4, 48.1, 45.1, 41.1, 33.0, 31.4, 29.7,
24.6; HRMS calcd for C20H24F3N2OS [M þ H]þ 397.1556 found
397.1572.

4.1.31. 5-(Thiophen-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl) pentan-1-one (9e) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 5-(thiophen-2-yl)pentanoic acid (77 mg,
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg,
0.43 mmol), anhydrous NEt3 (87 mL, 0.63 mmol) and anhydrous
DMF (4 mL) and following the general procedure described in
method 1 section 4.1.6. The reaction mixture was stirred at room
temperature for 23 h under a N2 atmosphere. DMF was removed
under reduced pressure and the residue was puriﬁed using column
chromatography (4:1, EtOAc:n-hexane) to give a brown solid,
120 mg (75%). Mp: 50e52  C; Rf: 0.5 (3:2, EtOAc:n-hexane); IR
(KBr): y (cm1) 2926, 1641, 1613, 1438, 1332, 1240; 1H NMR
(300 MHz, CDCl3): d (ppm) 7.49 (d, J ¼ 9.1 Hz, 2H), 7.08 (dd,
J ¼ 5.1 Hz, J ¼ 1.2 Hz, 1H), 6.92e6.88 (m, 3H), 6.77e6.76 (m, 1H),
3.78e3.75 (m, 2H), 3.62e3.59 (m, 2H), 3.27e3.22 (m, 4H), 2.83 (t,
J ¼ 7.2 Hz, 2H), 2.36 (t, J ¼ 7.2 Hz, 2H), 1.76e1.64 (m, 4H), 1.48e1.44
(m, 2H); 13C NMR (75 MHz, CDCl3): d (ppm) 171.5, 152.9, 145.3,
126.7, 126.5 (q, J ¼ 3.3 Hz), 124.1, 122.8, 124.6 (q, J ¼ 270.0 Hz), 121.7
(q, J ¼ 32.0 Hz), 114.9, 48.3, 48.0, 45.1, 41.1, 33.0, 31.5, 29.7, 28.8, 24.9.
HRMS calcd for C42H50F6N4O2S2Na [2 M þ Na]þ 843.3172 found
843.3152.

4.1.32. 3-(Thiophen-2-ylthio)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)propan-1-one (9f) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(50 mg, 0.22 mmol) and 3-(thiophen-2-ylthio)propanoic acid 8f
(37 mg, 0.19 mmol) using HOBt (30 mg, 0.22 mmol), TBTU (70 mg,
0.22 mmol), NEt3 (44 mL, 0.32 mmol) and DMF (2 mL) and following
the general procedure described in method 2 section 4.1.7. The
reaction mixture was stirred at room temperature for 18 h. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (3:2, EtOAc:Pet. ether (40e60  C))
to give a colourless oil, 45 mg (60%). Mp: 86e90  C; Rf: 0.75 (3:2,
EtOAc:Pet. ether (40e60  C)); IR (ATR): y (cm1) 2837, 1640, 1614,
1331, 1103; 1H NMR (500 MHz, CDCl3): d (ppm) 7.50 (d, J ¼ 8.7 Hz,
2H), 7.36 (dd, J ¼ 5.4, 1.2 Hz, 1H), 7.15 (dd, J ¼ 3.6, 1.2 Hz, 1H), 6.99
(dd, J ¼ 5.4, 3.6 Hz, 1H), 6.91 (d, J ¼ 8.7 Hz, 2H), 3.81e3.74 (m, 2H),
3.61e3.54 (m, 2H), 3.30e3.23 (m, 4H), 3.12 (t, J ¼ 7.3 Hz, 2H), 2.68 (t,
J ¼ 7.3 Hz, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 169.4, 152.9,
134.0, 134.0, 129.6, 127.7, 126.5 (q, J ¼ 3.8 Hz), 124.6 (q, J ¼ 271.3 Hz),
121.4 (q, J ¼ 32.8 Hz), 115.0, 48.3, 48.1, 45.0, 41.3, 34.1, 33.2; HRMS
calcd for C18H19F3N2OS2Na [M þ Na]þ 423.0783 found 423.0797.
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4.1.33. 1-(Thiophen-2-yl)-4-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)butane-1,4-dione (9g) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 4-oxo-4-(thiophen-2-yl)butanoic acid
(63 mg, 0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.69 mmol) and DMF (3 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
17 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2 EtOAc:n-hexane)
to give an off-white solid, 114 mg (84%). Mp: 172e176  C; Rf: 0.5
(3:2, EtOAc:n-hexane); IR (ATR): y (cm1) 2948, 1647, 1612, 1325,
1223; 1H NMR (500 MHz, CDCl3): d (ppm) 7.81 (d, J ¼ 3.6 Hz, 1H),
7.63 (d, J ¼ 4.9 Hz, 1H), 7.50 (d, J ¼ 8.6 Hz, 2H), 7.13 (t, J ¼ 4.3 Hz, 1H),
6.92 (d, J ¼ 8.6 Hz, 2H), 3.83e3.70 (m, 4H), 3.34e3.32 (m, 4H),
3.27e3.25 (m, 2H), 2.82 (t, J ¼ 6.5 Hz, 2H); 13C NMR (126 MHz,
CDCl3): d (ppm) 191.9, 170.1, 152.9, 143.9, 133.6, 132.1, 128.2, 126.5 (q,
J ¼ 3.8 Hz), 124.6 (q, J ¼ 271.3 Hz), 121.2 (q, J ¼ 32.6 Hz), 115.0, 48.2,
48.0, 45.0, 41.4, 34.2, 27.0; Anal. calcd for C19H19F3N2O2S C, 57.56; H,
4.83; N, 7.07; found C, 57.34; H, 4.62; N, 6.89; HRMS calcd for
C19H20F3N2O2S [M þ H]þ 397.1192 found 397.1179.
4.1.34. 4-(Thiophen-2-yl)butan-1-ol (10)
To a suspension of LiAlH4 (130 mg, 3.43 mmol) in THF (2.5 mL)
was added a solution of 4-(2-thienyl)butyric acid (500 mL,
3.43 mmol) in THF (2.5 mL). The suspension was stirred for 6 h at
room temperature. The reaction mixture was quenched with MeOH
(2 mL) and 10% aqueous NaOH (2 mL). The solution was neutralised
with 10% aqueous HCl (2 mL) and the aqueous layer extracted with
EtOAc (4  10 mL). The combined organic layers were dried over
MgSO4 and the residue puriﬁed using column chromatography
(DCM) to give a colourless oil, 481 mg (90%). Rf: 0.2 (DCM); IR
(ATR): y (cm1) 3329, 2934; 1H NMR (500 MHz, CDCl3): d (ppm)
7.11e7.05 (m, 1H), 6.92e6.87 (m, 1H), 6.79e6.74 (m, 1H), 3.60 (t,
J ¼ 6.6 Hz, 2H), 2.83 (t, J ¼ 7.6 Hz, 2H), 2.35 (bs, 1H), 1.77e1.68 (m,
2H), 1.64e1.55 (m, 2H); 1H NMR matches literature data [36]; 13C
NMR (126 MHz, CDCl3): d (ppm) 145.3, 126.8, 124.2, 123.0, 62.4, 32.1,
29.7, 28.0; HRMS calcd for C8H12OSNa [M þ Na]þ 179.0501 found
179.0509.
4.1.35. 4-(Thiophen-2-yl)butyl methanesulfonate (11)
Methanesulfonyl chloride (71 mL, 0.91 mmol) was added to a
solution of 4-(thiophen-2-yl)butan-1-ol 10 (135 mg, 0.86 mmol)
and NEt3 (142 mL, 1.01 mmol) in anhydrous DCM (3 mL) kept at 0  C.
The reaction mixture was maintained at 0  C for 1 h, followed by
warming to room temperature, where it was kept under vigorous
stirring and a N2 atmosphere for 3 h. The solvent was removed
under reduced pressure and puriﬁed using column chromatography (3:2, EtOAc:Pet. ether (40e60  C)) to give a colourless oil,
152 mg (75%). Rf: 0.7 (3:2, EtOAc:Pet.ether (40e60  C)); IR (ATR): y
(cm1) 2938, 1348, 1169, 930; 1H NMR (500 MHz, CDCl3): d (ppm)
7.18e7.07 (m, 1H), 6.95e6.88 (m, 1H), 6.81e6.76 (m, 1H), 4.27e4.20
(m, 2H), 2.98 (s, 3H), 2.92e2.83 (m, 2H), 1.87e1.75 (m, 4H); 13C
NMR (126 MHz, CDCl3): d (ppm) 144.3, 126.8, 124.5, 123.2, 69.6,
37.4, 29.2, 28.4, 27.6; HRMS calcd for C9H14O3S2Na [M þ Na]þ
257.0277 found 257.0271.
4.1.36. 1-(4-(Thiophen-2-yl)butyl)-4-(4-(triﬂuoromethyl)phenyl)
piperazine (12)
To a suspension of 4-(thiophen-2-yl)butyl methanesulfonate 11
(29 mg, 0.12 mmol) and Na2CO3 (26 mg, 0.24 mmol) in acetonitrile
(5 mL), was added 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(110 mg, 0.48 mmol). The mixture was heated at reﬂux for 24 h
under vigorous agitation and a N2 atmosphere. The solvent was
removed under reduced pressure and the residue was puriﬁed
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using column chromatography (3:2, EtOAc:n-hexane) to give a
white solid, 40 mg (91%). Mp: 78e80  C; Rf: 0.8 (3:2, EtOAc:nhexane); IR (ATR): y (cm1) 2839, 1613, 1325, 1099; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.48 (d, J ¼ 8.7 Hz, 2H), 7.12e7.10 (m,
1H), 6.94e6.90 (m, 3H), 6.81e6.78 (m, 1H), 3.32e3.24 (m, 4H), 2.87
(t, J ¼ 7.5 Hz, 2H), 2.62e2.54 (m, 4H), 2.42 (t, J ¼ 7.5 Hz, 2H), 1.74 (dt,
J ¼ 15.2, 7.5 Hz, 2H), 1.66e1.57 (m, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 153.3, 145.3, 126.7, 126.3 (q, J ¼ 3.3 Hz), 124.7 (q,
J ¼ 269.4 Hz), 124.1, 122.9, 120.4 (q, J ¼ 32.4 Hz), 114.4, 58.3, 53.0,
48.0, 29.8, 29.7, 26.3; HRMS calcd C19H24F3N2S [M þ H]þ 369.1067
found 369.1608.
4.1.37. 1-(4-(4-(Triﬂuoromethyl)phenyl)piperazin-1-yl)pentan-1one (14a) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(246 mg, 1.07 mmol) and pentanoic acid (106 mL, 0.98 mmol) using
HOBt (144 mg, 0.98 mmol), TBTU (343 mg, 0.98 mmol), anhydrous
NEt3 (216 mL, 1.56 mmol) and anhydrous DMF (6 mL) and following
the general procedure described in method 1 section 4.1.6. The
reaction mixture was stirred at room temperature for 23 h under a
N2 atmosphere. DMF was removed under reduced pressure and the
residue was puriﬁed using column chromatography (3:2, EtOAc:nhexane) to give an off-white solid, 178 mg (57%). Mp: 46e48  C; Rf:
0.6 (3:2, EtOAc:n-hexane); IR (KBr): y (cm1) 2935, 1650, 1631, 1450,
1337, 1228; 1H NMR (300 MHz, CDCl3): d (ppm) 7.49 (d, J ¼ 8.7 Hz,
2H), 6.92 (d, J ¼ 8.7 Hz, 2H), 3.79e3.76 (m, 2H), 3.66e3.62 (m, 2H),
3.30e3.23 (m, 4H), 2.37 (t, J ¼ 7.2 Hz, 2H), 1.69e1.59 (m, 2H),
1.45e1.32 (m, 2H), 0.94 (t, J ¼ 7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3):
d (ppm) 171.8, 152.9, 126.4 (q, J ¼ 3.3 Hz), 124.6 (q, J ¼ 268.8 Hz),
121.0 (q, J ¼ 32.7 Hz), 114.9, 48.3, 48.0, 45.1, 41.0, 33.0, 27.4, 22.6,
13.9; HRMS calcd for C16H22F3N2O [M þ H]þ 315.1679 found
315.1688.
4.1.38. 4-(1H-Pyrazol-4-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)butan-1-one (14b) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 4-(1H-pyrazol-4-yl)butanoic acid (52 mg,
0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.69 mmol) and DCM (3 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
24 h. DCM was removed under reduced pressure and the residue
was puriﬁed using column chromatography (3:2, EtOAc:n-hexane)
to give a brown solid, 116 mg (93%). Rf: 0.1 (3:2, EtOAc:n-hexane); IR
(ATR): y (cm1) 3055, 2947, 1649, 1614, 1226; 1H NMR (500 MHz,
CDCl3): d (ppm) 7.50 (d, J ¼ 8.5 Hz, 2H), 7.43 (s, 2H), 6.91 (d,
J ¼ 8.6 Hz, 2H), 5.57 (bs, 1H), 3.85e3.72 (m, 2H), 3.64e3.54 (m, 2H),
3.26 (s, 4H), 2.59 (t, J ¼ 7.4 Hz, 2H), 2.44e2.35 (m, 2H), 2.00e1.90
(m, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 171.4, 152.9, 132.9,
126.5 (q, J ¼ 3.9 Hz), 124.6 (q, J ¼ 271.3 Hz), 121.4 (q, J ¼ 32.6 Hz),
120.3, 115.0, 48.4, 48.1, 45.1, 41.2, 32.3, 26.2, 23.6; HRMS calcd for
C18H21F3N4ONa [M þ Na]þ 389.156 found 389.1563.
4.1.39. 1-(4-(4-(Triﬂuoromethyl)phenyl)piperazin-1-yl)ethanone
(16a) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(150 mg, 0.65 mmol) and acetic acid (33 mL, 0.59 mmol) using HOBt
(87 mg, 0.65 mmol), TBTU (208 mg, 0.65 mmol), NEt3 (131 mL,
0.94 mmol), and DMF (3 mL) and following the general procedure
described in method 2 section 4.1.7. The reaction mixture was
stirred at room temperature for 23 h. DMF was removed under
reduced pressure and the residue was puriﬁed using column
chromatography (4:1, EtOAc:n-hexane) to give an off-white solid,
117 mg (73%). Mp: 76e80  C; Rf: 0.5 (4:1, EtOAc:n-hexane); IR
(ATR): y (cm1) 3222, 1614, 1428, 1324, 1105; 1H NMR (500 MHz,

CDCl3): d (ppm) 7.50 (d, J ¼ 8.6 Hz, 2H), 6.92 (d, J ¼ 8.7 Hz, 2H),
3.84e3.71 (m, 2H), 3.70e3.57 (m, 2H), 3.35e3.19 (m, 4H), 2.14 (s,
3H); 13C NMR (126 MHz, CDCl3): d (ppm) 169.1, 152.9, 126.5 (q,
J ¼ 3.3 Hz), 124.6 (q, J ¼ 277.2 Hz), 121.2 (q, J ¼ 32.8 Hz), 115.0, 48.3,
48.0, 45.8, 41.0, 21.3; Anal. calcd for C13H15F3N2O C, 57.34; H, 5.55;
N, 10.29; found C, 57.16; H, 5.40; N, 9.87; HRMS calcd for
C13H15F3N2ONa [M þ Na]þ 295.1029 found 295.1037.
4.1.40. 1-(4-(4-(Triﬂuoromethyl)phenyl)piperazin-1-yl)octan-1one (16b) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and octanoic acid (62 mL, 0.39 mmol) using
HOBt (58 mg, 0.43 mmol), TBTU (138 mg, 0.43 mmol), anhydrous
NEt3 (87 mL, 0.63 mmol), and anhydrous DMF (4 mL) and following
the general procedure described in method 1 section 4.1.6. The
reaction mixture was stirred at room temperature for 22 h under a
N2 atmosphere. DMF was removed under reduced pressure and the
residue was puriﬁed using column chromatography (3:2, EtOAc:nhexane) to give a cloudy white oil, 88 mg (63%). Rf: 0.7 (3:2,
EtOAc:n-hexane); IR (neat): y (cm1) 2927, 1641, 1616, 1436, 1331,
1116; 1H NMR (300 MHz, CDCl3): d (ppm) 7.49 (d, J ¼ 8.7 Hz, 2H),
6.91 (d, J ¼ 8.7 Hz, 2H), 3.80e3.72 (m, 2H), 3.67e3.56 (m, 2H),
3.30e3.20 (m, 4H), 2.39e2.31 (m, 2H), 1.70e1.59 (m, 2H), 1.38e1.24
(m, 8H), 0.92e0.82 (m, 3H); 13C NMR (75 MHz, CDCl3): d (ppm)
171.8, 152.9, 126.4 (q, J ¼ 3.3 Hz), 124.6 (q, J ¼ 269.5 Hz), 121.2 (q,
J ¼ 32.7 Hz), 115.0, 48.4, 48.1, 45.2, 41.1, 33.3, 31.7, 29.4, 29.1, 25.3,
22.6, 14.1; HRMS calcd for C19H28F3N2O [M þ H]þ 357.2148 found
357.2136.
4.1.41. 5-Phenyl-1-(4-(4-(triﬂuoromethyl)phenyl)piperazin-1-yl)
pentan-1-one (16c) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(150 mg, 0.65 mmol) and 5-phenylpentanoic acid (105 mg,
0.59 mmol) using HOBt (87 mg, 0.65 mmol), TBTU (208 mg,
0.65 mmol), NEt3 (131 mL, 0.94 mmol), and DMF (5 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
21 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (4:1, EtOAc:n-hexane)
to give an orange oil, 150 mg (65%). Mp: 72e76  C; Rf: 0.7 (4:1,
EtOAc:n-hexane); IR (ATR): y (cm1) 2857, 1636, 1610, 1436, 1331,
1068; 1H NMR (500 MHz, CDCl3): d (ppm) 7.48 (d, J ¼ 8.7 Hz, 2H),
7.26e7.23 (m, 2H), 7.19e7.13 (m, 3H), 6.88 (d, J ¼ 8.7 Hz, 2H),
3.81e3.68 (m, 2H), 3.62e3.49 (m, 2H), 3.24e3.17 (m, 4H),
2.68e2.61 (m, 2H), 2.40e2.32 (m, 2H), 1.75e1.65 (m, 4H); 13C NMR
(126 MHz, CDCl3): d (ppm) 171.5, 153.0, 142.2, 128.5, 128.4, 126.5 (q,
J ¼ 3.8 Hz), 125.8, 124.7 (q, J ¼ 271.3 Hz), 121.2 (q, J ¼ 32.8 Hz), 115.0,
48.3, 48.1, 45.1, 41.1, 35.7, 33.1, 31.1, 24.9; Anal. calcd for
C22H25F3N2O C, 67.67; H, 6.45; N, 7.18; found C, 67.61; H, 6.51; N,
7.18; HRMS calcd for C22H26F3N2O [M þ H]þ 391.1992 found
391.1996.
4.1.42. 3-(Furan-2-yl)-1-(4-(4-(triﬂuoromethyl)phenyl)piperazin1-yl)propan-1-one (16d) [35]
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(100 mg, 0.43 mmol) and 3-(furan-2-yl)propanoic acid (54 mg,
0.39 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (138 mg,
0.43 mmol), anhydrous NEt3 (87 mL, 0.63 mmol), and anhydrous
DMF (4 mL) and following the general procedure described in
method 1 section 4.1.6. The reaction mixture was stirred at room
temperature for 22 h under a N2 atmosphere. DMF was removed
under reduced pressure and the residue was puriﬁed using column
chromatography (3:2, EtOAc:n-hexane) to give an orange solid,
43 mg (31%). Mp: 77e81  C; Rf: 0.6 (3:2, EtOAc:n-hexane); IR (KBr):
y (cm1) 2921, 1625, 1616, 1443, 1334, 1227; 1H NMR (300 MHz,

R. Devine et al. / European Journal of Medicinal Chemistry 202 (2020) 112416

CDCl3): d (ppm) 7.50 (d, J ¼ 8.6 Hz, 2H), 7.31e7.30 (m, 1H), 6.91 (d,
J ¼ 8.6 Hz, 2H), 6.29e6.27 (m, 1H), 6.05e6.04 (m, 1H), 3.80e3.79 (m,
2H), 3.61e3.58 (m, 2H), 3.26e3.21 (m, 4H), 3.08e2.97 (m, 2H),
2.76e2.67 (m, 2H); 13C NMR (75 MHz, CDCl3): d (ppm) 170.4, 154.6,
152.9, 141.1, 126.5 (q, J ¼ 3.7 Hz), 124.5 (q, J ¼ 269.2 Hz), 121.3 (q,
J ¼ 32.5 Hz), 115.0, 110.4, 105.6, 48.3, 48.1, 45.0, 41.2, 31.6, 23.8;
HRMS calcd for C18H20F3N2O2 [M þ H]þ 353.1471 found 353.1461.
4.1.43. 9-Oxo-9-(4-(4-(triﬂuoromethyl)phenyl)piperazin-1-yl)
nonanoic acid (16e) [35]
Prepared from methyl 9-oxo-9-(4-(4-(triﬂuoromethyl)phenyl)
piperazin-1-yl)nonanoate 16f (131 mg, 0.31 mmol) and KOH
(88 mg, 1.55 mmol) in EtOH (5 mL) heated at reﬂux for 3 h. The
solution was allowed to cool to room temperature and EtOH was
removed under reduced pressure. The residue was dissolved in H2O
(1 mL), the pH adjusted to pH ¼ 6 with 2 M aqueous HCl and the
aqueous layer extracted with DCM (20 mL, followed by 4  10 mL).
The organic layers were washed with brine (3  20 mL), dried over
MgSO4 and evaporated under reduced pressure to give a white
solid, 99 mg (80%). Mp: 90e92  C; Rf: 0.5 (1:19, MeOH:DCM); IR
(KBr): y (cm1) 2935, 1706, 1617, 1333, 1204; 1H NMR (500 MHz,
CDCl3): d (ppm) 7.50 (d, J ¼ 8.6 Hz, 2H), 6.93 (d, J ¼ 8.7 Hz, 2H),
3.82e3.75 (m, 2H), 3.67e3.61 (m, 2H), 3.32e3.23 (m, 4H),
2.40e2.29 (m, 4H), 1.70e1.58 (m, 4H), 1.39e1.31 (m, 6H); 13C NMR
(126 MHz, CDCl3): d (ppm) 178.3, 172.0, 153.1, 126.7 (q, J ¼ 3.8 Hz),
123.5 (q, J ¼ 269.1 Hz), 120.3 (q, J ¼ 32.7 Hz), 115.2, 48.6, 48.3, 45.4,
41.3, 34.0, 33.4, 29.3, 29.1, 29.0, 25.3, 24.8; Anal. calcd for
C20H27F3N2O3 C, 59.99; H, 6.80; N, 7.00; found C, 60.40; H, 6.83; N,
6.85; HRMS calcd for C20H28F3N2O3 [M þ H]þ 401.2407 found
401.2047.
4.1.44. Methyl 9-oxo-9-(4-(4-(triﬂuoromethyl)phenyl)piperazin-1yl)nonanoate (16f) [35]
Methyl hydrogen azelate (479 mg, 2.30 mmol), BOP (1140 mg,
2.60 mmol), anhydrous NEt3 (512 mL, 3.60 mmol), and anhydrous
DCM (20 mL) were placed in an oven-dried three neck ﬂask under a
N2 atmosphere. The resulting solution was stirred at room temperature for 15 min. 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(600 mg, 2.60 mmol) was added and the reaction mixture stirred
under a N2 atmosphere and monitored by TLC. After 16 h, DCM was
removed under reduced pressure and the resulting oil was acidiﬁed
to pH ¼ 3 using a 0.1 M aqueous HCl. The aqueous mixture was
extracted with DCM (20 mL, followed by 4  10 mL) and the organic
layer washed with a saturated aqueous solution of NaHCO3
(3  20 mL) and brine (3  20 mL). The organic layer was dried over
MgSO4 and the solvent removed in vacuo and the residue was puriﬁed using column chromatography (3:2, EtOAc:Pet. ether
(40e60  C)) to give an off-white solid, 952 mg (98%). Mp: 81e85  C;
Rf: 0.65 (3:2 EtOAc:Pet. ether (40e60  C)); IR (KBr): y (cm1) 2954,
1739, 1647, 1613, 1447, 1334, 1160; 1H NMR (500 MHz, CDCl3):
d (ppm) 7.49 (d, J ¼ 8.6 Hz, 2H), 6.92 (d, J ¼ 8.7 Hz, 2H), 3.85e3.71
(m, 2H), 3.72e3.52 (m, 5H), 3.39e3.14 (m, 4H), 2.32 (dt, J ¼ 29.1,
7.5 Hz, 4H), 1.69e1.58 (m, 4H), 1.34 (bs, 6H); 13C NMR (126 MHz,
CDCl3): d (ppm) 174.3, 171.7, 149.2, 126.5 (q, J ¼ 3.3 Hz), 124.5 (q,
J ¼ 269.7 Hz), 121.2 (q, J ¼ 32.8 Hz), 115.0, 51.5, 48.5, 48.2, 45.2, 41.1,
34.1, 33.2, 29.3, 29.1, 29.0, 25.2, 24.9; HRMS calcd for C21H30F3N2O3
[M þ H]þ 415.2203 found 415.2217.
4.1.45. N-(2-methoxyethyl)-9-oxo-9-(4-(4-(triﬂuoromethyl)
phenyl)piperazin-1-yl)nonanamide (16g) [35]
Prepared from 9-oxo-9-(4-(4-(triﬂuoromethyl)phenyl)piperazin-1-yl)nonanoic acid 16e (137 mg, 0.34 mmol) and 2methoxyethanamine (29 mL, 0.43 mmol) using HOBt (58 mg,
0.43 mmol), TBTU (140 mg, 0.43 mmol), anhydrous NEt3 (100 mL,
0.69 mmol) and anhydrous DMF (2 mL) and following the general
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procedure described in method 1 section 4.1.6. The reaction
mixture was stirred at room temperature under a N2 atmosphere
for 20 h. DMF was removed under reduced pressure and the residue
was puriﬁed using column chromatography (elution gradient 1:1
EtOAc:n-hexane to EtOAc:n-hexane 4:1) to give a white solid,
52 mg (34%). Mp: 88e92  C; Rf: 0.2 (4:1, EtOAc:n-hexane); IR (KBr):
y (cm1) 2932, 1676, 1636, 1618, 1442, 1344, 1208; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.50 (d, J ¼ 8.5 Hz, 2H), 6.92 (d,
J ¼ 8.6 Hz, 2H), 5.81 (bs, 1H), 3.81e3.73 (m, 2H), 3.66e3.58 (m, 2H),
3.48e3.40 (m, 4H), 3.35 (s, 3H), 3.31e3.23 (m, 4H), 2.39e2.32 (m,
2H), 2.19e2.14 (m, 2H), 1.68e1.59 (m, 4H), 1.39e1.30 (m, 6H); 13C
NMR (126 MHz, CDCl3): d (ppm) 173.1, 171.7, 152.9, 126.5 (q,
J ¼ 3.8 Hz), 124.6 (q, J ¼ 271.3 Hz), 121.3 (q, J ¼ 32.8 Hz), 115.0, 71.3,
58.7, 48.4, 48.1, 45.2, 41.1, 39.1, 36.7, 33.2, 29.2, 29.1, 29.0, 25.6, 25.2;
HRMS calcd for C23H35F3N3O3 [M þ H]þ 458.2625 found 458.2631.
4.1.46. 1-Methyl-4-(4-(triﬂuoromethyl)phenyl)piperazine (17)
Prepared from 1-(4-(triﬂuoromethyl)phenyl)piperazine 2a
(70 mg, 0.30 mmol) dissolved in absolute EtOH (3 mL) before formic
acid (200 mL, 5.23 mmol) and formaldehyde (147 mL, 1.54 mmol)
were consecutively added. The solution was heated at reﬂux for 3 h
after which the EtOH was removed under reduced pressure and the
residue dissolved in minimal H2O (2 mL). The aqueous solution was
neutralised to pH ~13 using saturated aqueous NaHCO3 (4 mL) and
extracted with DCM (4  10 mL). The organic layers were dried over
MgSO4 and concentrated in vacuo. The residue was puriﬁed using
column chromatography (1:1, EtOAc: Pet. ether (40e60  C)) to give
a white solid, 51 mg (70%). Rf: 0.1 (1:1, EtOAc:Pet. ether
(40e60  C)); IR (ATR): y (cm1) 2851, 1614, 1104; 1H NMR
(500 MHz, CDCl3): d (ppm) 7.47 (d, J ¼ 8.7 Hz, 2H), 6.92 (d,
J ¼ 8.7 Hz, 2H), 3.33e3.26 (m, 4H), 2.59e2.52 (m, 4H), 2.35 (s, 3H);
1
H NMR data matches literature data [37]; 13C NMR (126 MHz,
CDCl3): d (ppm) 153.3, 126.4 (q, J ¼ 3.8 Hz), 124.8 (q, J ¼ 271.1 Hz),
120.5 (q, J ¼ 32.7 Hz), 114.5, 54.8, 48.0, 46.1; 13C NMR data matches
literature data [37]; HRMS calcd for C12H16F3N2 [M þ H]þ 245.1260
found 245.1257.
4.1.47. 1-(Thiophen-2-yl)-4-(4-(4-(triﬂuoromethyl)phenyl)
piperidin-1-yl)butane-1,4-dione (18) [35]
Prepared from 4-(4-triﬂuoromethyl)phenyl)piperidine (99 mg,
0.43 mmol) and 4-oxo-4- (2-thienyl)butanoic acid (63 mg,
0.34 mmol) using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), NEt3 (100 mL, 0.51 mmol), and DCM (6 mL) and
following the general procedure described in method 2 section
4.1.7. The reaction mixture was stirred at room temperature for
19 h. DCM was removed under reduced pressure and the residue
was puriﬁed using column chromatography (4:1, EtOAc:n-hexane)
to give a white solid, 117 mg (87%). Rf: 0.3 (4:1, EtOAc:n-hexane); IR
(ATR): y (cm1) 2935, 1657, 1633, 1330, 1110; 1H NMR (500 MHz,
CDCl3): d (ppm) 7.82 (d, J ¼ 3.2 Hz, 1H), 7.63 (d, J ¼ 4.9 Hz, 1H), 7.57
(d, J ¼ 8.1 Hz, 2H), 7.32 (d, J ¼ 8.1 Hz, 2H), 7.17e7.08 (m, 1H), 4.79 (d,
J ¼ 11.6 Hz, 1H), 4.13 (d, J ¼ 14.3 Hz, 1H), 3.37e3.28 (m, 2H),
3.23e3.14 (m, 1H), 2.90e2.77 (m, 3H), 2.71e2.60 (m, 1H), 1.91 (dd,
J ¼ 31.5, 13.1 Hz, 2H), 1.75e1.57 (m, 2H); 13C NMR (126 MHz, CDCl3):
d (ppm) 192.2, 169.9, 149.2, 144.1, 133.6, 132.2, 128.9 (q, J ¼ 32.4 Hz),
128.2, 127.2, 125.6 (q, J ¼ 3.8 Hz), 124.3 (q, J ¼ 272.4 Hz), 46.0, 42.8,
42.5, 34.4, 33.6, 32.7, 27.3; HRMS calcd for C20H21F3NO2S [M þ H]þ
396.124 found 396.1251.
4.1.48. 1-(Thiophen-2-yl)-4-(4-(5-(triﬂuoromethyl)pyridin-2-yl)
piperazin-1-yl)butane-1,4-dione (19) [35]
Prepared from 1-(5-(triﬂuoromethyl)pyridin-2-yl)piperazine
(99 mg, 0.43 mmol) and 4-oxo-4-(thiophen-2-yl)butanoic acid
(63 mg, 0.34 mmol), using HOBt (58 mg, 0.43 mmol), TBTU (140 mg,
0.43 mmol), anhydrous NEt3 (100 mL, 0.69 mmol), and anhydrous
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DMF (3 mL) and following the general procedure described in
method 1 section 4.1.6. The reaction mixture was stirred at room
temperature for 17 h under a N2 atmosphere. DMF was removed
under reduced pressure and the residue was puriﬁed using column
chromatography (3:2 EtOAc:n-hexane) to give an off-white solid,
85 mg, (63%). Mp.: 204e206  C; Rf: 0.36 (3:2, EtOAc:Pet. ether
(40e60  C)); IR (KBr): y (cm1) 1655, 1638, 1329, 1102; 1H NMR
(500 MHz, CDCl3): d (ppm) 8.42 (s, 1H), 7.81 (dd, J ¼ 3.8, 1.1 Hz, 1H),
7.67 (dd, J ¼ 9.0, 2.4 Hz, 1H), 7.63 (dd, J ¼ 4.9, 1.1 Hz, 1H), 7.14 (dd,
J ¼ 4.9, 3.8 Hz, 1H), 6.66 (d, J ¼ 9.0 Hz, 1H), 3.83e3.69 (m, 6H),
3.67e3.60 (m, 2H), 3.34 (t, J ¼ 6.5 Hz, 2H), 2.82 (t, J ¼ 6.5 Hz, 2H);
13
C NMR (126 MHz, CDCl3): d (ppm) 191.9, 170.4, 160.0, 145.5 (q,
J ¼ 4.3 Hz), 143.9, 134.8 (q, J ¼ 3.2 Hz), 133.6, 132.1, 128.2, 124.4 (q,
J ¼ 270.9 Hz), 115.8 (q, J ¼ 33.2 Hz), 105.9, 44.9, 44.7, 44.4, 41.2, 34.2,
27.1; Anal. calcd for C18H18F3N3O2S C, 54.40; H, 4.57; N, 10.58; found
C, 54.39; H, 4.27; N, 10.59. HRMS calcd for C36H37F6N6O4S2
[2 M þ H]þ 795.2216 found 795.2223.
4.1.49. 1-(4-(3-Chloro-5-(triﬂuoromethyl)pyridin-2-yl)piperazin-1yl)-4-(thiophen-2-yl)butane-1,4-dione (20) [35]
Prepared from 1-(3-chloro-5-(triﬂuoromethyl)pyridin-2-yl)
piperazine (114 mg, 0.43 mmol) and 4-oxo-4-(thiophen-2-yl)
butanoic acid (63 mg, 0.34 mmol), using HOBt (58 mg, 0.43 mmol),
TBTU (140 mg, 0.43 mmol), anhydrous NEt3 (100 mL, 0.69 mmol),
and anhydrous DMF (3 mL) and following the general procedure
described in method 1 section 4.1.6. The reaction mixture was
stirred at room temperature for 18 h under a N2 atmosphere. DMF
was removed under reduced pressure and the residue was puriﬁed
using column chromatography (3:2 EtOAc:n-hexane) to give an offwhite solid, 102 mg (70%). Mp: 102e104  C; Rf: 0.5 (3:2, EtOAc:nhexane); IR (KBr): y (cm1) 2915, 1647, 1604, 1416, 1319, 1231, 844;
1
H NMR (300 MHz, CDCl3): d (ppm) 8.41e8.40 (m, 1H), 7.82e7.79
(m, 2H), 7.64 (dd, J ¼ 4.0 Hz, J ¼ 1.0 Hz, 1H), 7.15e7.12 (m, 1H),
3.80e3.72 (m, 4H), 3.57e3.54 (m, 2H), 3.50e3.47 (m, 2H), 3.33 (t,
J ¼ 9.0 Hz, 2H), 2.84 (t, J ¼ 9.0 Hz, 2H); 13C NMR (75 MHz, CDCl3):
d (ppm) 191.9, 170.2, 159.5, 143.9, 143.1 (q, J ¼ 3.7 Hz), 136.1 (q,
J ¼ 3.3 Hz), 133.5, 132.1, 128.6 (q, J ¼ 270.1 Hz), 128.1, 121.1 (q,
J ¼ 33.2 Hz), 121.0, 48.5, 45.1, 41.5, 34.2, 27.1; Anal. calcd for
C18H17F3N3O2SCl C, 50.06; H, 3.97; N, 9.73; found C, 50.14; H, 3.77;
N, 9.47; HRMS calcd for C18H18F3N3O2SCl [M þ H]þ 432.0755 found
432.0765.
4.1.50. 1-(4-(3-Chloro-5-(triﬂuoromethyl)pyridin-2-yl)piperazin-1yl)-3-(thiophen-2-ylthio)propan-1-one (21) (RTB70) [10,35]
Literature procedure [10]. Prepared from 1-(3-chloro-5-(triﬂuoromethyl)pyridin-2-yl)piperazine (698 mg, 2.63 mmol) and 3(thiophen-2-ylthio)propanoic acid 8f (450 mg, 2.39 mmol) using
HOBt (698 mg, 2.63 mmol), TBTU (767 mg, 2.63 mmol), anhydrous
NEt3 (532 mL, 3.82 mmol) and anhydrous DMF (10 mL) and
following the general procedure described in method 1 section
4.1.6. The reaction mixture was stirred at room temperature for 21 h
under a N2 atmosphere. DMF was removed under reduced pressure
and the residue was puriﬁed using column chromatography (3:2
EtOAc:n-hexane). The obtained product was dissolved in a minimal
amount of DCM and Pet. ether (40e60  C) was added until precipitation began. The solution and the precipitate were stored
at 20  C for 21 h, and the resultant crystals collected by vacuum
ﬁltration and washed with cold Pet. ether (40e60  C) (~20 mL) to
give white needles, 2.1 g (71%). 1H NMR: (300 MHz, CDCl3)
d 8.41e8.40 (m, 1H, H2), 7.79e7.78 (m, 1H, H4), 7.35 (dd, J ¼ 5.3 Hz,
J ¼ 1.2 Hz, 1H, H10), 7.15 (m, 1H, H8), 7.00e6.97 (m, 1H, H9),
3.78e3.75 (m, 2H*), 3.58e3.55 (m, 2H*), 3.50e3.46 (m, 4H*), 3.11
(t, J ¼ 7.1 Hz, 2H, H6), 2.68 (t, J ¼ 7.1 Hz, 2H, H5) [10]; 13C NMR:
(75 MHz, CDCl3) d 170.1 (C]O), 160.1 (C3), 143.6 (q, J ¼ 4.1 Hz, C2),
136.7 (q, J ¼ 3.3 Hz, C4), 134.6 (C7, C10), 130.2 (C8), 128.3 (C9), 123.8

(q, J ¼ 270.0 Hz, CF3), 121.7 (CeCl), 121.2 (q, J ¼ 33.0 Hz, C1), 49.1
(C*), 45.7 (C*), 42.0 (C*), 34.8 (C6), 33.9 (C5) [10].

4.1.51. 1-(4-Phenylpiperidin-1-yl)-4-(thiophen-2-yl)butan-1-one
(22)
Prepared from 4-phenylpiperidine (69 mg, 0.43 mmol) and 4(thiophen-2-yl)butanoic acid (50 mL, 0.34 mmol) using HOBt
(58 mg, 0.43 mmol), TBTU (140 mg, 0.43 mmol), NEt3 (100 mL,
0.51 mmol), and DCM (6 mL) and following the general procedure
described in method 2 section 4.1.7. The reaction mixture was
stirred at room temperature for 18 h. DCM was removed under
reduced pressure and the residue was puriﬁed using column
chromatography (3:2, EtOAc:n-hexane) to give a clear oil, 105 mg
(98%). Rf: 0.6 (3:2, EtOAc:n-hexane); IR (ATR): y (cm1) 3026, 2933,
1636, 1435;1H NMR (500 MHz, CDCl3): d (ppm) 7.32 (m, J ¼ 7.6 Hz,
2H), 7.25e7.16 (m, 3H), 7.13 (dd, J ¼ 5.1, 1.2 Hz, 1H), 6.93 (dd, J ¼ 5.1,
3.4 Hz, 1H), 6.89e6.78 (m, 1H), 4.82 (d, J ¼ 13.2 Hz, 1H), 3.91 (d,
J ¼ 13.5 Hz, 1H), 3.09 (m, J ¼ 13.2, 2.1 Hz, 1H), 2.94 (t, J ¼ 7.4 Hz, 2H),
2.73 (m, J ¼ 12.2, 3.6 Hz, 1H), 2.63 (m, J ¼ 13.0, 2.1 Hz, 1H),
2.46e2.38 (m, 2H), 2.07 (m, J ¼ 7.4 Hz, 2H), 1.93e1.84 (m, 2H),
1.67e1.54 (m, 2H); 13C NMR (126 MHz, CDCl3): d (ppm) 170.8, 145.3,
144.6, 128.6, 126.8, 126.8, 126.5, 124.5, 123.2, 46.2, 42.8, 42.4, 34.0,
32.9, 32.3, 29.4, 27.2; HRMS calcd for C19H23NOSNa [M þ H]þ
336.1393 found 336.1393.

4.1.52. Methyl 4-(thiophen-2-yl)butanoate (24)
4-(2-Thienyl)butyric acid (1 mL, 6.86 mmol) was dissolved in
MeOH (10 mL) and concentrated H2SO4 (1.15 mL, 21.95 mmol) was
added was added dropwise. The reaction mixture was stirred at
room temperature for 22 h. MeOH was removed under reduced
pressure and the residue dissolved in minimal H2O. The pH was
adjusted to pH ¼ 7.0 using 2 M HCl and the aqueous layer was
extracted with DCM (15 mL x 3). The combined organic layers were
dried over MgSO4 and the solvent removed under reduced pressure. The residue was puriﬁed using column chromatography to
give a clear oil, 1.03 g (81%). Rf: 0.7 (9:1, Pet. ether
(40e60  C):EtOAc); 1H NMR (300 MHz, CDCl3): d (ppm) 7.09 (dd,
J ¼ 5.1 Hz, J ¼ 1.2 Hz, 1H), 6.90e6.78 (m, 1H), 6.78e6.77 (m, 1H),
2.85 (t, J ¼ 7.0 Hz, 2H), 3.65 (s, 3H), 2.35 (t, J ¼ 7.0 Hz, 2H), 2.04e1.94
(m, 2H); 1H NMR data matches literature data [38]; HRMS calcd for
C9H13O2S [M þ H]þ 207.0450 found 207.0456.

4.2. NADH:ubiquinione oxidoreductase inhibition
Enzyme activity was examined in permeabilised mitochondria,
isolated from rat liver, as previously described [10]. Basal activity of
permeabilised mitochondria, incubated with 50 mM K2HPO4 pH
7.5, 3 mg/mL fatty acid free bovine serum albumin, 300 mM KCN and
100 mM NADH, was measured at 340 nm for 1 min. The oxidation of
NADH was initiated with the addition of 60 mM ubiquinone and the
resulting decrease in absorbance was followed for 3 min. Varying
concentrations of test compounds were then added and absorbance was measured for a further 3 min. To determine the percentage activity of NADH:ubiquinone oxidoreductase, the slope of
the line obtained with the addition of ubiquinone was divided by
the slope of the line produced with the addition of the test compound. This value was then expressed as a percentage, relative to
the value calculated for the vehicle control, DMSO, and the protein
concentration of the mitochondrial sample. Speciﬁcity of the assay
was conﬁrmed with the addition of rotenone, a known inhibitor of
NADH:ubiquinone oxidoreductase. Compounds were tested at 5
different concentrations, in triplicate, to generate IC50 values.

R. Devine et al. / European Journal of Medicinal Chemistry 202 (2020) 112416

4.3. Cell culture and glucose uptake
C2C12 mouse muscle cells (Sigma-Aldrich, 91031101), were
maintained in high glucose (4500 mg/mL) Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 100 mg/mL penicillin/streptomycin, 2 mM L-glutamine (complete medium) and 10% (v/v) foetal
bovine serum FBS. When 80% conﬂuent, differentiation into myotubes was induced with complete medium supplemented with 2%
(v/v) horse serum. Differentiated C2C12 were incubated with the
compound of interest for 16 h in complete medium supplemented
with 0.1% (v/v) horse serum. Following stimulation, cells were
washed with Krebs Ringer Buffer (KRB); 136 mM NaCl, 20 mM
HEPES, 4.7 mM KCl, 1 mM MgSO4, 1 mM CaCl2, 4.05 mM Na2HPO4,
0.95 mM NaH2PO4, pH 7.4, warmed to 37  C. Cells were then
incubated with 1 mCi/mL [3H]-2-deoxyglucose for 10 min at 37  C.
To terminate the assay, cells were washed three times with ice-cold
KRB and lysed in 0.1% (w/v) SDS for 30 min at 37  C. Radioactivity of
the lysates, diluted 1:4 in scintillation ﬂuid, was determined with a
1450 Microbeta Liquid Scintillation Counter (PerkinElmer),
expressing results as counts per minute (CPM). Results were normalised to the protein content of the sample using the bicinchoninic acid method [10,23],.
4.4. Molecular modelling
Of the 26 active compounds in the glucose uptake assay, 17
compounds had a p value < 0.001 signiﬁcance; 3 had a P
value < 0.01 and 6 at a P value of <0.05. The remaining 18 compounds were not signiﬁcant in the assay. Using Biovia Discovery
Studio [24] Pareto clustering was performed to generate a training
(20% of compounds) and test (80% of compounds) data set for
subsequent pharmacophore model generation and validation.
4.5. Pharmacophore model
For the pharmacophore model development the following
compounds were assigned as most active with a principal number
of 2 in Biovia Discovery Studio 4.0 (3a (RTC1), 9d, 16b, 16e); as
active with a principal number of 1 (5c, 3i), and inactive with a
principal number of 0 (5a, 3f, 9a).
3D conformations of the molecules were generated with the
CAESAR algorithm and active molecules with in vitro activity were
used to build a common features pharmacophore using uses the
HipHop module of the Catalyst program. Descriptors such as
hydrogen bond donor (HBD), hydrogen bond acceptor (HBA), hydrophobic (HY), ring aromatic (RA), positive ionizing (PI), and
negative ionizing (NI) were utilised. The ﬁtting method was set to
rigid and the maximum omitted features to 1; a maximum of 50
exclusion volumes was allowed. With the result of the common
feature pharmacophore model generation, desired chemical groups
were identiﬁed using the feature mapping protocol. To make a
prediction about the future performance of the developed pharmacophore model a ROCs curve was generated with a score of
0.712. The remaining compounds were used as a test set to validate
the developed pharmacophore model. This test set was screened
through the developed pharmacophore model to access its ability
to distinguish active from inactive compounds.
4.6. In silico pharmacokinetics
In silico absorption, distribution, metabolism, excretion and
toxicity (ADMET) studies were performed using Biovia Discovery
Studio 4.0. The module uses six mathematical models, to quantitatively predict properties by a set of rules/keys that specify
threshold ADMET characteristics for the chemical structure of the
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molecules. These include predictive models for human intestinal
absorption (HIA) [25,27], aqueous solubility [26], blood brain barrier penetration, cytochrome P450 2D6 enzyme inhibition [28],
plasma protein binding [29], and hepatotoxicity [30].
4.7. In vitro pharmacokinetics
Pharmacokinetic analysis was carried out as a service by Pharmidex, London, UK. See supporting information.
4.8. Thermodynamic solubility
Thermodynamic solubility was measured at concentrations of
1 mg/mL (2.61 mM, n ¼ 3) and 0.1 mg/mL (261 mM, n ¼ 3). Compounds were equilibrated in 5% (v/v) DMSO in PBS. Thermodynamic solubility was measured at 21  C for 24 h. Samples were
centrifuged at 15,000 g for 10 min and the supernatant was assayed
by LC-MS/MS. See supporting information.
4.9. P-glycoprotein (P-gp) mediated efﬂux
All compounds were dissolved in 100% DMSO to provide 10 mM
stock solutions from which donor (dose) solutions were prepared
in DMEM to give a ﬁnal drug concentration of 10 mM. All dose solutions contained 10 mM propranolol as an internal standard.
hMDR1-MDCK seeded ﬁlters were exposed to a ﬁxed volume of
the donor solution containing the compound of interest and its
ability to traverse the monolayer and appear in the receiver
compartment measured over a 30 min period. Bidirectional
permeability measurements were derived by examining the
transfer of compound in both the apical to basolateral compartment, and vice versa. Sample analysis was conducted using LC-MS/
MS with the detection settings optimised for each test compound,
(n ¼ 3). See supporting information.
4.10. Hepatocyte and microsomal stability
Buffer containing 3a (RTC1) (1 mM) was added to a microtitre
plate followed by hepatocytes. The reaction was incubated at 37  C
for up to 120 min. Acetonitrile, with an internal standard, was
added to stop the incubation. Samples were centrifuged and the
supernatant was then analysed by HPLC-MS/MS for the parent
compound, n ¼ 2. See supporting information.
4.11. Liver microsomal cytochrome analysis
CYP baculosomes containing cDNA for a single human P450
isozyme were added to a microtitre plate containing 10 mM 3a
(RTC-1), followed by the ﬂuorogenic substrate and NADPH. The
reaction was incubated at 37  C, for at least 60 min, before ﬂuorescence was measured, n ¼ 3. See supporting information.
4.12. Plasma stability
Buffer containing 1 mM 3a (RTC-1) was added to a microtitre
plate followed by blood plasma. The reaction was incubated at 37  C
for 60e120 min. Acetonitrile, with an internal standard, was added
to stop the reaction. Samples were centrifuged, and the supernatant
was analysed by HPLC-MS/MS for the parent compound. See supporting information.
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